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ABSTRACT

Bacterial resistance to antibiotic therapies, especially to β-lactams, is an
increasing problem. Β-lactamases are the main source of clinical resistance to these
antibiotics, and the class D β-lactamases are one of the most rapidly expanding classes of
these enzymes. The emergence of class D enzymes with the ability to hydrolyze the
newest family of β-lactams - the carbapenems - is a serious concern for the healthcare
system as carbapenems are last resort antibiotics: ideal for severe infections after other
therapies have failed. Class D β-lactamases are very diverse in terms of sequence and
substrate profile, and it remains unclear what factors affect the enzymes’ ability to
hydrolyze certain classes of antibiotics (e.g. carbapenems or cephalosporins). The β5-β6
loop has been previously shown to affect the substrate profile of OXA enzymes, for
carbapenems in particular. This work examines the effects of selected mutations in the
β5-β6 loop on the proteins’ dynamics via Molecular Dynamics simulations. OXA-24 (a
carbapenemase) and three mutants (M223A, G224D, P227S) were simulated for 40 nsec,
and the trajectories revealed that all three mutations alter the dynamics of the enzyme.
Our data show that the mutations affect the flexibility of several crucial segments of the
enzyme structure, the overall compactness of the protein, as well as the size of the active
site. Our results suggest that the β5-β6 loop can affect the substrate profile of OXA-24 by
modulating the enzyme’s dynamics in a way that is consistent with substrate profile
expansion, in particular with the ability to bind 3rd generation cephalosporins.
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CHAPTER I
INTRODUCTION
1. Antibiotics
Antibiotics are chemical agents that impede the growth of bacteria
(bacteriostatics) or kill the bacteria (bacteriocidals). There are many classes of antibiotics
(Talaro 2011), including: (i) the β-lactams, targeting bacterial cell wall transpeptidases;
(ii) polymyxins, targeting the bacterial cell membrane; (iii) sulfonamides, targeting
dihydropteroate synthetases involved in folate synthesis; (iv) tetracyclines and (v)
aminoglycosides, which target the 30S ribosomal subunit; (vi) quinolones, targeting DNA
gyrases; (vii) macrolides, which target the 50S ribosomal subunit. These compounds have
been extremely useful in saving lives. However, a misuse of antibiotics, both in human
therapies, and in livestock, combined with a lack of understanding of the gravity of the
problem led to the problem of bacterial resistance to antibiotics that we are experiencing
today (Neu 1992; Bax 2001; CDC 2013). Solving this problem will require many
changes, such as improved public education about antibiotics/antibiotic resistance, and
removal of antibiotics from animal feed in addition to the development of novel antibiotic
compounds (Bush 2011a).
1A. β-Lactam Antibiotics
β-lactam antibiotics target DD-transpeptidases (E.C. 3.4.16.4, also called
penicillin binding proteins (PBPs)) in bacteria. DD-transpeptidases cross-link the
peptidoglycan chains in bacterial cell walls, and are inhibited upon binding β-lactam
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antibiotics. A lack of cross-links without these enzymes providing maintenance of the
cell walls will result in cell death from lysis (Talaro 2011).
Unlike other antibiotics whose targets have human homologs, β-lactam antibiotics
are the safest antibiotics available (Salkind 2001). They are also cheap to manufacture on
a large scale, with a kilogram of penicillin costing only $15-20 at the beginning of the
millennium (Elander 2003). The name β-lactam comes from the β-lactam ring (Fig. 1A),
a cyclic amide that is found within all classes of related antibiotics

A

(Fig. 1B-D).

C

B

D

Fig. 1: β-Lactam Core Structures. A: β-lactam ring. B: Left, core structure of
penicillins. C: Middle, core structure of cephalosporins. D: Right, core structure of
monobactams.
The first β-lactam antibiotic discovered was penicillin in 1928 by Alexander
Fleming and, it has been used clinically since the 1940s. While its discovery was an
important step in treating bacterial infections, it was recognized almost immediately that
penicillin was relatively ineffective against Gram-negative bacteria (Hall 1994). It was
not until ampicillin entered the market in 1963 that an antibiotic was effective against
both Gram-positive and Gram-negative bacteria (Medeiros 1997). However, the first
penicillin resistant strain was discovered as early as 1944 (Kirby 1944). Since then
multiple other types of β-lactams have been discovered and further developed, including
the cephalosporins (Fig. 1B), and monobactams (Fig. 1D).
20

The most recent class of β-lactam antibiotics to
be discovered and used clinically are the carbapenems
(Fig. 2).The first carbapenem introduced into the United
States was imipenem in 1987. Since then three more
carbapenems have been approved for clinical use:
meropenem in 1996, ertapenem in 2001, and
doripenem in 2007. Carbapenem antibiotics
are considered to be last resort antibiotics
(Carrër 2008). While each carbapenem has a
specific therapeutic role, they are generally

Fig. 2: Carbapenem Core Structure &
Doripenem. Top: Core structure of
carbapenems. Bottom: Structure of
doripenem.

used to treat patients with moderate to
severe infections (Zhanel 2007, Keam

2008). Within the group of β-lactam antibiotics, carbapenems are considered to be
clinically “stable.” This term is used to describe their intrinsic resistance to many βlactamases (i.e. β-lactamases are not able to hydrolyze the β-lactam ring in these
compounds). In addition to their β-lactamase resistance, newer carbapenems are also
resistant to renal dehydropeptidase (E.C. 3.4.13.19) hydrolysis, which was a common
problem with imipenem. The resistance of carbapenems against most β-lactamases is
attributed to a trans-α-1-hydroxyethyl group at position 6 (Fig. 2, R1 substituent). Renal
dehydropeptidase resistance was accounted for due to a 1-β-methyl group placed at the
R2 position (Fig. 2) (Zhanel 2007). This resistance to hydrolysis by a majority of βlactamases made carbapenems the most important last resort clinical agents used in
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complicated nosocomial infections (Cornaglia 2010). Thus, emergence of strains that do
inactivate carbapenems is a grave problem.
2. Clinical Aspects of Antibiotic Resistance
Many different drug-resistant bacteria species have become the root-cause of
serious health complications (Sharma 2011) – a problem that is estimated to cost the U.S.
economy in excess of $20 billion according to the Centers for Disease Control and
Prevention (Roberts 2009; CDC 2013). Various strains of S. aureus are now implicated in
fatal cases of sepsis, and necrotizing fasciitis due to methicillin (Boyle-Vavra 2007) and
vancomycin (Bozdogan 2003) resistance. Respiratory infections as well show antibiotic
resistance, with different strains of S. pneumonia and S. pyogenes providing penicillin
and macrolide resistance (Albrich 2004). Acinetobacter baumannii has become an
increasingly important pathogen, especially with bloodstream infections (CDC 2004).
Much of A. baumannii’s resistance is due to class D β-lactamases, which will be
discussed in following sections.
3. Diversity of Mechanisms of Antibiotic Resistance
Ultimately, every antibiotic exerts evolutionary pressure on bacteria to develop
survival and resistance mechanisms. In the case of β-lactams, major mechanisms of
resistance are: β-lactamases; the overexpression of β-lactamases in susceptible strains
(Guitérrez 2007); antibiotic sensing domains (Zeng 2013); mobile genetic elements to
facilitate rapid spread of resistance genes (Rumbo 2011); penicillin binding protein
mutations (Katayama 2004), efflux pumps (Nakae 1999), and mutations in transporters
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reducing influx and permeability of antibiotics (Li 2009). The most common mechanism
is via β-lactam ring cleavage by β-lactamases.
4. β-Lactamases
4A. Classes and Diversity
β–lactamases (E.C. 3.5.2.6) are major mediators of bacterial resistance to
antibiotic therapies, and pose a serious threat to the most widely used class of antibiotics
(Ferech 2006). They form a large family (500+) of distinct enzymes (Bush 2010). All of
these enzymes are believed to have evolved from ancestral PBPs, which helped
synthesize cell walls (Kelly 1986; Massova 1998; Hall 2004)
Currently there are two classification systems for the β–lactamase family: one
based on sequence similarity (Ambler 1980) and the other – based on functional profile
(Bush 2010), i.e. the types of β–lactam substrates that a given subgroup can hydrolyze.
According to sequence-based classification there are four classes of β-lactamases: A, B,
C, and D (Hall 2005). Classes A, C, and D are serine-hydrolase enzymes (Fig. 3), while
class B enzymes are metalloenzymes that use a Zn2+ ion for catalysis. In classes A, C,
and D the hydrolysis process occurs in two steps: acylation of the enzyme by the
antibiotic (Fig. 3A-B), and deacylation that yields in inactivated product (Fig. 3C-F).
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Fig. 3: Serine-based Mechanism of β-Lactam Hydrolysis. Mechanism depicts the roles
of the active site serine (nucleophile), and water molecule which assists with the deacylation.
The mechanism requires serine activation by a general base: a glutamate residue serves this
role in class A enzymes (Matagne 1998), and a carboxylated lysine (full side chain not shown)
residue in class D enzymes. Figure adapted from Che (2012).
The functional classification developed by Bush et al. (1989; 2010) divides the
enzymes into groups based on their clinical activity. Factors such as substrate(s), and
inhibitory molecules are taken into account. This classification has only 3 groups: Group
1 being solely cephalosporinases (class C enzymes); Group 2 being serine β-lactamases
(classes A and D), containing multiple functional subgroups with some enzymes showing
multispecificity towards ligands; and Group 3 being the metallo-β-lactamases (class B
enzymes) (Fig. 4).
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Fig. 4: Functional Classification of β-Lactamases. Abbreviations are: Cb, carbapenems;
Cf, early marketed cephalosporins; CA, clavulanic acid; EDTA, ethylenediaminetetraacetic
acid; Esc, Expanded spectrum cephalosporins; M, monobactam; Pn, penicillins. Figure
adapted from Bush (2013).

4B. Extended-Spectrum β-Lactamases versus CPase Activity
β-lactamases that are capable of hydrolyzing third generation cephalosporins (Fig.
5), in addition to other narrow-spectrum antibiotics like penicillin are generally referred
to as Extended Spectrum β-lactamases (ESBLs) (Bradford 2001). There are currently
over 200 ESBLs within the molecular classes A, C, and D. Most of these enzymes do not
exhibit CPase activity, and carbapenem antibiotics are thus the treatment of choice in the
case of infections caused by ESBL expressing strains (Paterson 2005). However, this
increased use of carbapenems in response to ESBL activity is likely a factor in applying
selective pressure for organisms to acquire and express Carbapenem Hydrolyzing class D
β-lactamases (CHDLs).
The molecular explanation for why certain enzymes show ESBL activity while
others do not is generally attributed to the ability of the active site to accommodate the
bulkier substituents that are present on third generation cephalosporins, such as
25

ceftazidime and ceftriaxone (Fig. 5). Specific examples will be discussed in the following
sections.

Fig. 5: Structures of Ceftazidime & Ceftriaxone. Left: Ceftazidime. Right: Ceftriaxone.

4B-1. Mutations Enlarging the Active Site Promote Cephalosporinase Activity
Numerous enzymes have gained ESBL activity through unique mutations. The
class C enzyme GC1 achieved this function through a three amino acid insertion within
the Ω loop (Crichlow 1999; Fig. 7). The exact sequence of the amino acids appears to
play no significant role, but the length of the insertion does as it causes the Ω loop to shift
and open up the active site. SHV-2, a class A enzyme, contains a Gly238Ser mutation
which causes the β3 strand to shift away from the enzyme’s Ω loop as Ser238 hydrogen
bonds with Asn170. This ~3Å shift opens up the active site to larger substrates (Nukaga
2003). Both support the hypothesis that the size of the binding pocket is vital for
accommodating large substituents. The class D enzyme, OXA-163, differs from OXA-48
(a CHDL) by a 1 amino acid substitution (S212D), and a 4 amino acid deletion (R214P217) after the KTG family motif on the β5 strand. This sequence change causes
26

increased cephalosporinase activity (Poirel 2011). While the authors do not detail a
structure/functional relationship for this newly gained activity, based on how previous
enzymes have acquired ESBL activity the likely cause of OXA-163’s ESBL activity is an
opening of the active site.
Multispecificity of a β-lactamase is an undesirable trait from a clinical
perspective. Since carbapenems tend to be the treatment of choice for ESBL-producing
infections, and 3rd generation cephalosporins for CHDL-producing infections, bacteria
which are capable of producing multispecific (i.e. both CHDL and ESBL) resistance
enzymes pose a major threat to the current arsenal of antimicrobials. Any CHDL and
ESBL-producing bacterium drastically limits the options for antibacterial chemotherapy
to drugs with undesirable side-effects – such as those observed with linezolid, an
antibiotic that when used over the long term may cause GI complications and
thrombocytopenia (Kalil 2010); or polymyxins, which have shown neurotoxic effects
(Grill 2011).
4B-2. OXA-24 Variant Exhibits Cephalosporinase and CPase Activity
The molecular mechanisms of ligand selection are not well understood and, given
that a single amino acid substitution can have a profound effect on substrate profile
(Afzal-Shah 2001; Nukaga 2003; Kaitany 2013), is it vital to elucidate (and predict) the
effects of specific mutations. This can help predict evolutionary pathways of these
enzymes, and perhaps lead to more effective antimicrobial chemotherapeutics. In this
project we aim to help understand the mutational effects that affect both CHDLs
and ESBLs in OXA-24 and its variants. OXA-160 is a P227S mutation of OXA-24
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(Tian 2011) which confers increased resistance to third generation cephalosporins,
ampicillin, and aztreonam. It increases activity against doripenem, but decreases activity
against imipenem (Mitchell 2015).
4C. Class D Enzymes and OXA-24 as Focus of this Thesis
4C-1. Unique Features
There are currently over 200 unique enzymes in the class, and more are expected
as the class is currently experiencing the fastest growth out of all β-lactamase subfamilies
(Fig. 6). It should be noted that while the CMY class C β-lactamases, and class A KPC
enzymes have higher rates of growth, the class D enzymes has the most unique enzymes
of all the subfamilies.

Fig. 6: Growth Rate of β-Lactamase Classes. Class D enzymes are only designated as
OXA. Class A enzyme designations are TEM, SHV, CTX, GES, and KPC. Class B enzymes
are IMP, and VIM. Class C enzyme family is CMY. Figure adapted from Bush et al. (2011b).

Class D β-lactamases, like the class A and C enzymes, use an active-site serine for
hydrolysis (Ledent 1993), but are most likely distant relatives of these enzymes (Massova
1998) and contain many unique features. Unlike the other two classes, class D enzymes
28

contain a rare, modified, amino acid: a carboxylated lysine, which is critical for catalytic
activity (Golemi 2001). The carboxylysine residue acts as the general base in the
hydrolysis mechanism, playing a particularly essential role in the deacylation step of
catalysis (Schneider 2009b).
4C-2. Conserved Motifs and Residues
In addition to the general base and catalytic serine, highly conserved motifs and
residues were identified in the class D family. Highly conserved motifs include (residue
numbers correspond to PDB 3ISG): P65-[AD]STFK, S115-xV, [YF]141-GN, and K212[TS]G (Bou 2000). Highly conserved residues (>95 %) outside of those motifs are: G128,
W160, I167, L184, W228, G231, and F243 as revealed by multiple sequence alignment
of 80+ unique OXA sequences (Szarecka 2011).
4C-3. Structural Features
Structures of OXAs are highly conserved (as revealed by a number of crystal
structures of various class D enzymes). Crystal structures are available for OXA-1 (PDB
1M6K), OXA-2 (1K38), OXA-10 (1FOF), OXA-13 (1H87), OXA-23 (4K0X), OXA-24
(2JC7), OXA-45 (4GN2), OXA-46 (3IF6), OXA-48 (3HBR), OXA-58 (4OH0), OXA146 (4K0W), OXA-160 (4X56), and OXA-225 (4X55). The fold (Fig. 7) includes a
helix-only domain, and an α/β domain. The helical domain contains the active site
PASTFK motif, the P loop, and other active site stabilizing elements (e.g. Trp167). The
α/β domain contains the β5-β6 loop, the K[ST]G motif, and both the N and C-termini. All
of these elements will be discussed in further detail in the sections to follow.
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4C-4. Class D CPases and
OXA-24 Subgroup
Fairly recently, multiple
class D enzymes with CPase
activity (functional subgroup 2df,
Fig. 4) have been identified
(Afzal-shah 2001). These newer
class D members are the main
source of carbapenem resistance
in A. baumannii infections (Poirel
2006), and are becoming
increasingly common (Queenan
2007). Distinct Class D CPase

Fig. 7: Class D Conserved Secondary Elements.
Catalytic PASTFK motif colored green, P loop
colored yellow, Ω loop colored red, β5-β6 loop
colored blue.

subgroups are OXA-23, 24, 48, 51, 58, and 228 (Bonnin 2012). The focus of this
research is on the parent enzyme OXA-24, and three OXA-24 mutants (M223A,
G224D, P227S). OXA-24 (NCBI RefSeq YP_002967455.1) is a CPase that was
discovered in Spain over a decade ago in a strain of A. baumannii (Bou 2000). It is
identical to OXA-40 and is sometimes referred to as OXA-24/40. Initially OXA-24 was
thought to only be chromosomally encoded (Bou 2000), but recent studies have shown
that horizontal transfer events of the blaoxa-24 gene can occur (Rumbo 2011) resulting in
an enzyme with an increased potential for pathogenic spread. OXA-24 has spread, from
Spain to Portugal (Da Silva 2004), France (Quinteira 2007), Italy (D’Andrea 2009), and
the United States (Tian 2011). Based on our sequence alignment OXA-24 is also a parent
30

enzyme to multiple variants, including OXA-25, 26, 72, 139, 143, 160, 182, 207, 231,
253, and 255. Based on the MSA I performed using M-Coffee (Wallace 2006), OXA-24
shares 99% sequence identity with OXAs-25, 26, 72, 139, 160, and 207; 88% identity
with OXA-143, 231; 89% identity with OXA-182; 90% identity with OXA-253; and 87%
identity with OXA-255 (Table 14, Appendix C). These group members have spread as
well, such as OXA-72 in Colombia (Montealegre 2012), the United States (Tian 2011),
China (Wang 2007), and Lithuania (Povilonis 2012).
OXA-24 is capable of hydrolyzing other antibiotics in addition to carbapenems.
Hydrolysis of ampicillin is relatively similar to that of imipenem and doripenem (Km/kcat
= 3.1 ±0.4 μM-1s-1 for doripenem and imipenem, 2.6 ±0.3 μM-1s-1 for ampicillin)
(Mitchell 2015). OXA-24 binds the carbapenems much more tightly than ampicillin; the
Km for ampicillin is ~200 times greater than that of imipenem. However, OXA-24 turns
over ampicillin at a much greater rate than the carbapenems (Kcat of 480 ±20s-1 for
ampicillin, and 0.074 ±0.001s-1 and 2.1 ±0.1s-1 for doripenem and imipenem
respectively). The hydrolysis of 3rd generation cephalosporins in quite poor: Kcat/Km for
cefotaxime is 0.00051 ±0.00005 μM-1s-1, while ceftazidime hydrolysis is not detectable
(Mitchell 2015).
4D. Current Knowledge on Factors Determining ESBL or CHDL Activity in OXAs
The mechanism through which some class D enzymes acquire new function is
poorly understood, and evolutionary pathways that govern the functional diversity and
multispecificity within class D β-lactamases must be elucidated. Detailed information is
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needed on which residues assist, and which residues hinder various stages of the catalytic
cycle for various classes of β-lactams.
Several factors have been proposed in the literature with regard to the mechanism
of ESBL and CHDL activities. As mentioned before, in the majority of cases, βlactamases cannot exhibit both ESBL and CHDL activity. Thus, increased ability to
hydrolyze cephalosporins reduces the ability of catalyzing carbapenems and vice-versa.
OXA-160 (OXA-24 P227S) is a notable exception in this respect.
In the case of ESBL, the size of the binding pocket is vital as 3rd generation
cephalosporins contain bulky substituents (Fig. 5) that need to be packed inside the active
site without affecting the position of the β-lactam ring with respect to the catalytic
residues. Thus, mutations that increase the size of the binding cavity should promote
ESBL activity. It is equally important that no steric barriers hinder the entrance to the
pocket. Indeed, Kaitany et al. (2013) suggested that the Tyr112-Met223 interaction in
OXA-24 forms a bridge that prevents binding of such bulky ligands and may facilitate
carbapenem binding.
In the case of CPase activity, the following factors have been proposed in the
literature: (1) the ability to recruit a necessary water molecule to complete the catalytic
cycle (Schneider 2009a); (2) interactions between the hydroxyl group in position R1 (Fig.
2) with the carboxylysine may diminish the latter’s ability to serve as the general base
(Schneider 2011); (3) intramolecular reactions such as tautomerization of the pyrroline
ring within the substrate that may hinder deacylation (Schneider 2011); (4) mutations that

32

promote decarboxylation of the general base (Schneider 2011); (5) mutations in the loop
adjacent to the catalytic center (De Luca 2011).
With regard to factor (5), a recent study by De Luca et al. (2011) reported that the
β5-β6 alone is able to “switch” on the CPase activity. When OXA-10’s (a non-CPase) β5β6 sequence (residues 221-228, OXA-24 numbering) was replaced with that of OXA24’s the hybrid enzyme showed CPase activity. The authors hypothesized that the β5-β6
loop impacts the binding mode of carbapenems, facilitating hydrolysis. Thus, it is clear
that this loop is involved in CHDL activity although the mechanism through which the
β5-β6 loop affects substrate selection is not well understood. It should be noted that the
“β5-β6” term is not technically correct when identifying the loop in OXA-24. OXA
structures vary in the exact number of stands in their extended β sheet so the strand
numbering varies from enzyme to enzyme. The actual loop in OXA-24 WT would be the
β4-β5 loop (Fig. 36, Appendix C), but because the term was defined using OXA-48
(Docquier 2009; De Luca 2011), we have decided to continue using this nomenclature.
In addition, OXA-160 (Tian 2011) and other studies (Kaitany 2013; Mitchell
2015) revealed that single amino-acid mutations within the β5-β6 loop in CPases impart
the ability to hydrolyze 3rd generation cephalosporins, i.e. a multispecific ESBL-CHDL
enzyme emerged.
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5. Research objectives
In light of the above findings, I have set the following aim as the research
objective of my thesis:
Aim: To elucidate the mechanism through which the β5-β6 loop affects the ligand
binding and selectivity of the OXA-24 enzyme, in particular the binding of 3rd generation
cephalosporins and doripenem.
Hypothesis: Since the β5-β6 loop is not directly involved in the ligand binding or in
hydrolysis, I hypothesize that mutations within this loop have an indirect affect – through
modulating the enzyme dynamics.
Aim 1a: Analysis of Molecular Dynamics simulation trajectories of OXA-24 wild-type,
M223A, G224D, and P227S mutants. Simulation trajectories (40 nsec) provide insight
into the residue fluctuations in different variants, size and shape of the active site,
conformational flexibility of the β5-β6 and Ω loops, and the stability of the catalytic
center.
Aim 1b: Docking simulations of representative antibiotics to multiple trajectory frames.
Differences in the conformational ensembles of different variants can be identified within
the trajectories, and representative frames then serve as docking targets for various
classes of antibiotics. This will provide insight into the ability of the variants to
accommodate various types of β-lactams.
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CHAPTER II
METHODS
1. Sequence Analysis
CPase sequences from the OXA-24 family were collected by performing a protein
BLASTp search of the OXA-24 sequence on the non-redundant protein sequences
database through the National Center for Biotechnology Information
(http://www.ncbi.nlm.nih.gov/), and saving all sequences which shared ≥85% identity
with OXA-24. Representative sequences from other class D families – determined via
Poirel et al. (2010) - were acquired from the NCBI Protein database. This cutoff percent
was self-chosen as all members of the OXA-24 subgroup share >85% identity with every
other member. The lowest identity shared between two members of the OXA-24
subgroup is 86%. OXA-24 only shares 62% identity with CPase OXA-51; identities
between OXA-24 and other class D CPases are lower still. Therefore, the 85% sequence
identity cutoff was chosen to best represent enzymes that are currently part of the OXA24 subgroup.
The Multiple Sequence Alignment (MSA) tool M-Coffee (Wallace 2006) was
employed for motif discovery and sequence alignment. M-Coffee was run through its
online server at http://tcoffee.crg.cat/apps/tcoffee/do:mcoffee (Moretti 2007). M-Coffee
uses several MSA algorithms, and then combines those alignments into one, final
alignment. All eight default MSA methods were utilized for aligning the collected class D
sequences: PCMA (Pei 2003), POA (Lee 2002), DIALIGN-T (Subramanian 2005),
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MAFFT (Katoh 2005), MUSCLE (Edgar 2004), ProbCons (Do 2005), CLUSTAL W
(Thompson 1994), and T-Coffee (Notredame 2000)
2. Molecular Dynamics
2A. Theoretical Background
MD simulations are a deterministic method of modeling the physical movements
of atoms within a user-defined system. While many methods exist for sampling the
conformational space of proteins (e.g. Monte Carlo simulation), MD simulations allow
for the conformational space to be sampled in a time-dependent manner; essentially
allowing for the system to evolve on its own biological time-scale (Karplus 2002).
The determination of atomic movements requires a potential energy function; also
known as a “force field.” The force field approximates the energy of a system by
expressing it as a function of the system’s structure (atomic positions) (Fig. 8). From the
potential energy, it is possible to determine the individual forces acting on each atom
within the system. Then, by applying Newton’s equations of motion to the N-atom
system over small time-scales, a time-dependent evolution of the protein structure (also
known as a trajectory) can be obtained.
Current force fields rely on empirical parameters; numerical constants which
describe all of the potential interactions between all types of atoms present within the MD
simulation. Standard sets of parameters have been developed for proteins and nucleic
acids, and implemented in simulation packages such as CHARMM (Brooks 2009) or
AMBER (Case 2005). However, additional parameters are needed to model novel or
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modified residues. In the case of this work, additional parameters were needed to model
the carboxylated lysine present within OXA-24.
𝑈(𝑅⃑ ) = ∑ 𝐾𝑏 (𝑏 − 𝑏0 )2
𝑏𝑜𝑛𝑑𝑠
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Fig. 8: CHARMM Force Field. This function determines potential energy of a
conformation using the following molecular components: bonds, angles, Urey-Bradley,
dihedrals, impropers, electrostatic interactions, and Van der Waals interactions. Figure
adapted from Brooks et al. (2009).
In the case of the CHARMM force field the parameters fall into the following
categories: force constants, equilibrium values, multiplicities (number of energy minima
present during the rotation of dihedrals), and other factors such as atomic charges and
Van der Waals parameters. The covalent bonds, bond angles, Urey-Bradley term – an
additional harmonic term that helps reproduce crystal structure geometries and
vibrational spectra more consistently by describing certain distances between the first and
third atoms in an angle (MacKerell Jr 1998), though not all force fields use this term
(Wang 2003) - and improper dihedrals, are all treated as “springs,” i.e. represented by a
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harmonic potential. The farther from their respective equilibrium values, the higher the
overall energy a particular conformation will have. The non-bonded pairs portion of the
equation represents the interactions between two charged particles, qi and qj, with a
distance between them of rij. 𝜀0 is the permittivity of a vacuum, and ε is the classic
dielectric constant of the medium separating the charged particles. The Lennard-Jones, or
𝑚𝑖𝑛
12-6, potential is used to calculate Van der Waals forces between two atoms. 𝜀𝑖𝑗
is the

depth of the potential energy well between two particles, 𝑟𝑖𝑗𝑚𝑖𝑛 is the minimum distance
where the two particles interact, and 𝑟𝑖𝑗 is the current distance between both atoms.
CMAP is a torsional angle correction term, which helps with certain backbone
inconsistencies for alanine, glycine, and proline that were observed previously in the
CHARMM force field (MacKerell Jr 2004).
Modeling the protein’s environment is also key to obtaining realistic trajectories.
MD simulations typically use either an implicit or explicit solvent model. Implicit
solvation approximates the effects of water on a simulation by modeling water as a
dielectric continuum, instead of individual molecules. While these models are less
computationally demanding, they fall short when modeling many important protein-water
interactions (Tan 2006). Explicit solvent models include every water molecule present
within the system. These models generally provide more detailed information about
solvent effects on the protein, but this level of detail comes at the cost of computational
speed. Explicit water models tend to differ from one another in the number of interaction
points present on each water molecule. These can range from simple two-site models
(Dyer 2009), to five-site models that not only model each atom, but represent the lone
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electron pairs (Mahoney 2000). Typically, MD simulations use either a three-site model
(such as TIP3P), or a four-site model.
2B. Computational Details
OXA-24 WT and the P227S mutant were constructed using the previously
published OXA-24 WT crystal structure (PDB ID 3PAE). Mutating Pro227 to serine was
accomplished using the MMTSB script library (Feig 2004). The CHARMM script library
was used to add hydrogen atoms, and to create protein structure files (PSF). Protonation
states were set to coincide with neutral pH. System charge was brought to 0 by
selectively deprotonating Lys40 and Lys242. Both residues are incapable of directly
interacting with the active site, and are exposed to the solvent; no effects of the
deprotonation on the system are expected. Both structures were solvated with TIP3P
(Jorgensen 1983) with the box dimensions of 90 Å x 70 Å x 65 Å.
OXA-24 G224D and the M223A were set up using a crystallographic OXA-24
G224D structure (Mitchell, unpublished data). These structures have two additional
residues present on the N-terminus, an asparagine and phenylalanine. These two residues
are located away from the active site and are not expected to affect the system. System
charge was brought to 0 by selectively deprotonating Lys244 (identical to Lys242 in WT
and P227S) for the G224D mutant; both Lys 42 (identical to Lys40 in WT and P227S)
and Lys244 were deprotonated in the M223A mutant. All methods required to set up both
the G224D and M223A mutant are otherwise identical to the methods employed to set up
the WT and P227S mutant simulations. Box dimensions for both proteins are 90 Å × 67
Å × 62 Å.
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The CHARMM22 force field (Brooks 2009) and CHARMM 35a1 simulation
package were used to perform the MD simulations. Topology and parameter files were
modified to include entries for the carboxylated lysine (Simakov and Wymore,
unpublished data; Appendix A). All systems were minimized for 500 steps using the
Steepest Descent algorithm, followed by Adopted Basis Newton-Raphson until the
gradient threshold of 0.01 kcal/Å-2 was archived. All systems were then heated from 10K
to 300K over 30,000 steps (1 fsec/step). An NPT ensemble was then employed to
stabilize the box conditions; done for 20,000 steps (1 fsec/step). Harmonic constraints
were applied to the protein during these stages (minimization, heating, NPT): the SHAKE
algorithm, which held bonds containing hydrogens near equilibrium values; and a 5
kcal/mol penalty to positional deviations on the protein’s non-hydrogen atoms. The
productive simulation (excluding energy minimization) was performed at the Pittsburgh
Supercomputing Center using an NVT ensemble, SHAKE algorithm, Leapfrog algorithm
for integration of the potential energy function, and a time-step of 2 fsec. The first 1 nsec
of the NVT trajectories was treated as an equilibration period. Total NVT simulation time
of all systems was 39 nsec. Rectangular periodic boundary conditions were employed;
particle mesh Ewald was used for electrostatic calculations; and a non-bonded cutoff of
10 Å with a switching function was utilized throughout all stages of the simulation.
3. MD Trajectory Analysis
VMD (Humphrey 1996) was used to analyze the trajectories and render images.
Frames were aligned by the protein Cα atoms using the RMSD Visualizer Tool plugin.
Unless specified, frame 0 was used as the reference frame (first frame of the NVT portion
of the simulation). RMSDs were calculated using the RMSD Visualizer Tool – reference
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frame identical to trajectory alignment. RMSF, average structures, and Rgyr calculations
were calculated with the Tk console using VMD’s built-in functions for each. RMSF,
average structures, and Rgyr procedures were performed using the last 22 nsec of the
trajectories (see the appropriate sections in CHAPTER III).
The Python script which calculated the active site volume was written by Brian
Mullen (Mullen and Szarecka, unpublished data). The code uses the Quickhull algorithm
(Barber 1996), to create a convex hull with triangular facets which encloses the atoms of
the specified binding pocket. Techniques for calculating volume of the resulting threedimensional surface are extended from two-dimensional calculations. In two dimensions,
the area of an arbitrary polygon can be calculated by taking the sum of the areas of a set
of triangles, each with a base at one of the sides, and an apex at the center of the shape. In
three dimensions, the same method can be used with tetrahedrons. The atomic selection
used to define the active site can be found in Table 15 (Appendix C). The active site
atoms were selected to best represent how OXA-24 accommodates substrates. Since
entrance to the OXA-24 active site is essentially regulated by the Tyr112-Met223
hydrophobic bridge, atom selections were chosen to best represent this information.
Heatmaps generated from the volume script were created using the statistical
software RStudio (http://www.rstudio.com/). These heatmaps were generated using
Script 6 (Appendix B).
Hydrogen bonds (HB) were considered present in our simulation if the donor and
acceptor heavy (oxygen, nitrogen) atoms are less than 3.2 Å from each other (Arunan
2011). When taking into account donor-hydrogen-acceptor angles, a conservative range
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of 120-180° was employed. Since authors differ on what the correct geometric criteria of
HB in proteins are (Arunan 2011; Torshin 2002), we decided to adopt the above ranges as
representing the unequivocal and strong HB contributions. For example, other sources in
the literature on the subject describe hydrogen bonding with liberal donor-acceptor
distances of less than 3.9 Å, and donor-hydrogen-acceptor angles greater than 90.0°
(Torshin 2002).
4. WT and P227S Structure Selection
Φ/Ψ-based selection of WT and P227S structures were performed to acquire
unique conformations for molecular docking, and to detect differences between the
conformational ensembles in both proteins. Every 2 psec of the last 22 nsec was loaded,
and the φ and ψ angles for each β5-β6 loop residue was determined and plotted. These
Ramachandran plots were subsequently overlaid to observe differences between WT and
P227S. Regions on the Ramachandran plot which were occupied by only one of the
enzymes were considered unique, and an individual point was chosen (by eye) to be used
as a representative structure.
5. Molecular Docking
5A. Theoretical Background
Molecular docking is a computational technique for the prediction and modeling
of protein-ligand interactions. Ideally, accurate binding affinities are predicted along with
the correct poses of the ligand. Several algorithms have been implemented for docking,
for example incremental construction algorithms – where small portions of the ligand are
placed into the active site and scored for the best position, other fragments are then added
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on and scored until the entire ligand is “built” into the active site (Rarey 1996); and
genetic algorithms (GAs).
GAs are used by many docking programs – such as AutoDock4 (Morris 2009),
and GOLD (Jones 1997) - to determine the optimal position of the ligand in relation to
the receptor. GAs are conformational search algorithms that attempt to imitate the
process of natural selection. The best solution to a problem (best binding position in a
receptor) is therefore the solution with the best “fitness.” In the case of molecular
docking, the best fitness is given to the receptor-ligand conformation with the lowest
energy. The Lamarckian GA present in AutoDock4 is a combination of both a GA, and a
local search method. The “Lamarckian” aspect of this algorithm comes from JeanBaptiste Lamarck, who believed that traits acquired through an individual’s life will be
passed on to their offspring. This is essentially a phenotypic change which brings about a
genotypic change. This hybrid algorithm starts with the mapping of phenotype to
genotype. All rotatable bonds and the xyz position of the ligand within the search box are
“coded by” genes and chromosomes. For a user-specified number of individuals (i.e.
population size), all of these values are randomized initially. The “fitness” (binding
energy) is evaluated for all individuals and individuals are allowed to reproduce; the
chromosomes and genes defining each individual’s state may undergo crossing-over
(depending on the user-defined rate of crossing-over). Mutation then occurs at a defined
rate, which randomly alters genes. Just before the next generation begins, local searches
are done at a user-defined rate. This local search - the Lamarckian aspect of the algorithm
- allows for a further exploration of an individual’s torsional space. The individuals that
undergo a local search have their corresponding genes altered to reflect the local search.
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The next generation begins, and the processes are repeated until either all generations
have passed, or all energy evaluations have been performed regardless of the number of
generations that have been passed. The search space of the algorithm is organized in a 3dimensional box, or grid. This grid consists of a user-specified number of points along
each of the x, y, and z directions. The energy of each atom type present in the ligand will
be evaluated at each point using AutoDock4’s free energy function, and the total ligand
energy within the binding site is a combination of all of the atoms’ energies.
5B. Computational Details
Docking to selected conformations was carried out using AutoDockTools4 and
AutoDock4 (Morris 2009). The antibiotic structure of doripenem was downloaded and
saved from PubChem (http://pubchem.ncbi.nlm.nih.gov/) in the 3D SDF format.
Antibiotic 3D SDF files were converted to PDB files using the Online SMILES
Translator and Structure File Generator (http://cactus.nci.nih.gov/services/translate/). The
carboxylate group of doripenem was deprotonated using VMD to best represent the drug
in physiological conditions. Hydrogen atoms were added to antibiotic structures using
AutoDockTools4, and edited using VMD. Only polar receptor hydrogens were utilized
during docking runs, and Kollman partial charges (Singh 1984) were added to receptor
atoms. Search parameters regarding the GA were identical for all docking simulations:


Grid Spacing = 0.225



# of GA Runs = 100



Population Size = 750



Maximum # of Energy Evaluations = 1.0x108
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Maximum # of Generations = 5.0x104



Maximum # of Individuals that Automatically Survive = 1



Rate of Gene Mutations = 0.02



Rate of Crossover = 0.8



GA Crossover mode = “twopt”



Mean of Cauchy distribution for gene mutation = 0.0



Variance of Cauchy distribution for gene mutation = 1.0



# of generations for picking worst individual = 10
All other docking/local search parameters were set as defaults. Grid box size was

dependent upon the receptor, as active site elements may have undergone rearrangements
during the MD simulation. For each unique conformation, grid boxes were centered upon
the following atoms, and had the following grid sizes (# of x, y, and z points):


3PAE_Target.pdb: Centered on Arg261’s Cζ with grid size of 120x100x110.
Structure used for docking validation. This is a WT OXA-24 structure which does
not contain the KCX, instead an aspartate is present. Structure was modified
directly from PDB 3PAE, where only one protein chain was used as the receptor
for the docking of acylated doripenem.



oxa24wtsys1.pdb: Centered on Arg261’s Cζ with grid size of 120x100x110.
Structure used for docking validation. This is a WT OXA-24 structure which does
contain the KCX. This structure was taken from the MD setup just prior to energy
minimization. Only the protein chain was used as the receptor for the docking of
acylated and un-bound doripenem,
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wt_trp190.pdb: Grid box for doripenem was centered on Ser81’s Oγ with grid
size of 120 x 110 x 110. This is the WT structure utilized from the Trp221 φ/ψ
structure selection.



wt_pro196.pdb: Grid box for doripenem was centered on Ser81’s Oγ with grid
size of 110 x 100 x 110. This is the WT structure utilized from the Pro/Ser227
φ/ψ structure selection.



ps_trp190.pdb: Grid box for doripenem was centered on Ser81’s Oγ with grid size
of 110 x 100 x 100. This is the P227S structure utilized from the Trp221 φ/ψ
structure selection.



ps_ser196.pdb: Grid box for doripenem was centered on Ser81’s Oγ with grid size
of 110 x 100 x 100. This is the P227S structure utilized from the Pro/Ser227 φ/ψ
structure selection.
All docking simulations were performed using the Lamarckian GA on the

Phoenix Computing Cluster at Grand Valley State University (supported by NSF Grant
No. CNS-1228291). Docking results were analyzed in VMD.
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CHAPTER III
RESULTS
1. Determination of OXA-24 Subfamily
The sequences retrieved from the non-redundant protein database through NCBI
can be found on the following page in Table 1. Approximately 11 enzymes (as designated
by Parental Enzyme) were determined to be part of the OXA-24 subgroup. Other parental
CPase and non-CPase sequences were saved for comparison. The MSA that resulted from
M-Coffee can be found in the Supplementary Data (Fig. 37, Appendix C). While the
primary goal of the MSA was to determine if any unique motifs were present in only the
OXA-24 subgroup, the members of the OXA-24 subgroup were also determined, as
previous attempts to organize the class D family were incomplete (Poirel 2010). The
motifs that are truly unique to only the OXA-24 subgroup are small in number. Some
motifs appear in the OXA-24 family, and one other CPase subgroup. One example is a
Gln50-Thr-Gln motif which appears in every member of the OXA-24 subgroup, but also
in OXA-228. On the whole the MSA did not provide any additional motifs for analysis
within the MD simulations. However, one unique feature of the β5-β6 loop in CPase
OXAs is the presence of a hydrophobic residue (typically a valine, or isoleucine for
OXAs-23 and 48) at position 225 (OXA-24 numbering). No non-CPase OXA in the table
below contained a hydrophobic residue in the homologous position. This does not mean
that this pattern is universal, but the trend is present amongst the enzymes collected.

47

Enzyme

NCBI Accession #

Parental Enzyme

CPase

OXA-1

AAA91586.2

OXA-1

No

OXA-2

YP_006953608.1

OXA-2

No

OXA-5

CAA41211.1

OXA-5

No

OXA-10

YP_008658337.1

OXA-10

No

OXA-20

AAC23554.1

OXA-20

No

OXA-23

ABK34775.1

OXA-23

Yes

OXA-24

YP_002967455.1

OXA-24

Yes

OXA-25

AAG35607.1

OXA-24

Yes

OXA-26

AAG35608.1

OXA-24

Yes

OXA-48

AAP70012.1

OXA-48

Yes

OXA-51

CAC83905.2

OXA-51

Yes

OXA-58

AAW57529.1

OXA-58

Yes

OXA-63

AAU88145.1

OXA-63

No

OXA-72

YP_008090878.1

OXA-24

Yes

OXA-139

CAQ51348.1

OXA-24

Yes

OXA-143

ACX70402.1

OXA-24

Yes

OXA-160

ADB28891.1

OXA-24

Yes

OXA-182

ADK92148.1

OXA-24

Yes

OXA-207

AFK28473.1

OXA-24

Yes

OXA-228

AFM55001.1

OXA-228

Yes

OXA-231

AFG29918.1

OXA-24

Yes

OXA-253

AGK07368.1

OXA-24

Yes

OXA-255

AGK07369.1

OXA-24

Yes

Table 1: Class D Representative Sequences. Non-CPase enzymes were collected to
determine if discovered motifs were conserved amongst only CPases, or only OXA-24related CPases. Members of the OXA-24 subgroup are shown as having OXA-24 as the
parental enzyme.
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2. Comparison of Mutant Dynamics
2A. Trajectory RMSDs
2A-1. All Protein RMSD
Stability of the simulations was evaluated using all-Cα RMSD of each enzyme
(Fig. 9). RMSD calculations were performed using the initial frame of the NVT
simulation as the reference. Trajectories were aligned by all Cα atoms.

All Cα

All Cα

Fig. 9: All-Cα RMSD of Entire Protein.
All simulations showed the characteristic increase and leveling of all-Cα RMSD
values. Because RMSD is a commonly accepted measure of structural drift throughout
the simulation, WT, M223A, and P227S trajectories were considered stable as large
deviations were not observed past the extended 18 nsec equilibration period.
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Interestingly, the P227S mutant shows lower RMSD values than the WT for the majority
of the productive trajectory (i.e. from 18 nsec onward), while the M223A mutant shows
the opposite behavior. The behavior of the G224D mutant has been unique in that RMSD
values vary more dramatically (for example, around the 5 and 17 nsec time points). This
makes us uncertain about the successful stabilization of the G224D system. The G224D
peaks are caused by large fluctuations of the N-terminus; N-terminal Cαs in the high
RMSD frames deviate by ~23 Å from the reference frame (Fig. 38, Appendix C), but the
N-terminal residues (His32, Ile33, Ser34) do not form interactions with other residues.
While the G224D mutant may not have yet stabilized, in the following sections we use
the last 22 nsec as productive trajectory. It should also be mentioned that the enzymes’ P
loops may not have been sufficiently sampled due to the fact that large loop movements
of proteins tend to occur on the μsec timescale (Dror 2012).

2A-2. RMSD of Loops
P loop
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P loop

Ω loop

Ω loop

β5-β6 loop
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β5-β6 loop

Fig. 10: Cα RMSD of Protein Loops. Residue spans are: P loop, residues 93-120; Ω loop,
residues 154-176; β5-β6 loop, residues 221-228.
The RMSD drift calculations are present in Table 2.

Whole

P Loop: Cα

Ω Loop: Cα

β5-β6 Loop:

Protein: Cα

Atoms (Å)

Atoms (Å)

Cα Atoms (Å)

Atoms (Å)
WT

1.6 ±0.1

1.7 ±0.5

1.4 ±0.2

2.2 ±0.5

M223A

1.8 ±0.2

3.1 ±0.5

1.0 ±0.1

1.4 ±0.3

G224D

1.4 ±0.3

2.0 ±0.5

0.9 ±0.2

0.8 ±0.2

P227S

1.3 ±0.2

2.1 ±0.6

1.0 ±0.2

1.2 ±0.3

Table 2: RMSD Drift. RMSD drifts are calculated using the last 22nsec of the trajectory.
RMSD drift is calculated as the average RMSD.
Loop regions were expected to contribute greatly to the overall RMSD drift. In
the case of OXA-24, we were interested in the P loop, Ω loop, and the β5-β6 loop, with
the P loop being particularly difficult to stabilize over a relatively short trajectory span.
As shown in Table 2, we observe rather low values of RMSD for the β5-β6, and Ω loops,
but the P loop experiences much higher drift overall, particularly for M223A. In all
mutants both β5-β6 and Ω loops have lower RMSD values than WT overall.
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2A-3. RMSD of Active Site
The modality of the active site residues was measured as the RMSD of PASTFK,
KSG, SxV, and Arg261 motifs using both the RMSD of only Cα atoms, and all atoms to
reveal deviations from the initial structure (Fig. 11).

PASTFK Cα Atoms

PASTFK Cα Atoms

PASTFK All Atoms
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Other Active Site Residues Cα Atoms

Other Active Site Residues Cα Atoms

Other Active Site Residues All Atoms

Fig. 11: RMSD of Active Site. Other active site residues are: Ser128 and Val130 (SxV
motif), Lys218, Ser219, and Gly220 (KSG motif), as well as Arg261. PASTFK motif starts
with Pro79.
The RMSD drift for the RMSDs in Fig. 11 are present in Table 3.
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PASTFK

PASTFK

Other Active

Other Active

Motif: Cα

Motif: All

Site Residues:

Site Residues:

Atoms (Å)

Atoms (Å)

Cα Atoms (Å)

All Atoms (Å)

WT

1.0 ±0.2

1.4 ±0.2

1.1 ±0.2

1.6 ±0.1

M223A

1.5 ±0.2

2.1 ±0.2

1.5 ±0.2

1.9 ±0.1

G224D

0.7 ±0.1

1.3 ±0.1

1.2 ±0.3

1.8 ±0.2

P227S

1.0 ±0.2

1.5 ±0.2

1.2 ±0.2

1.7 ±0.1

Table 3: RMSD Drift of Active Site. RMSD drifts are calculated using the last 22nsec of
the trajectory. RMSD drift is calculated as the average RMSD. Other active site residues are:
Ser128, Val130, Lys218, Ser219, Gly220, and Arg261. PASTFK motif starts with Pro79.

The PASTFK motif shows changes in RMSD in all mutants, but only large
deviations in the M223A mutant when all atoms are examined. A similar pattern is
present in the other active site residues, but not to the same extent. The M223A RMSD
peak in Fig. 11 Other Active Site Residues Cα/All Atoms (around 7 nsec) corresponds to a
conformational shift in the protein backbone where Ser128 and Val130 are located. Both
of the residues’ Cαs shift ~4 Å from the reference frame (Fig. 39, Appendix C). Overall,
M223A and G224D (to a lesser extent) mutants are most affected.
2B. Internal Flexibility of Mutants
The effects of β5-β6 loop mutations on the global dynamics of the protein can
also be studied through the relative average flexibilities of different regions of the protein
calculated over the entire trajectory – the Root Mean Square Fluctuation (RMSF).
Differences in RMSF were calculated for all mutants with respect to the WT (Fig. 12-13,
Table 4).
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RMSF Difference (Å)
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Fig. 12: ΔRMSF between Mutants & WT. M223A: ΔRMSF between M223A and WT.
G224D: ΔRMSF between G224D and WT. P227S: ΔRMSF between P227S and WT.
ΔRMSF was calculated by subtracting the Cα RMSF values of the WT from the Cα RMSF
values of the specified mutant. Values above the zero line indicate increased fluctuations in
the mutant over the WT, while values below the line indicate decreased fluctuations.
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Fig. 13: RMSF of WT & Mutants.
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190

210

230

250

270

Mutant

Residues with Decreased

Residues with Increased Fluctuations Relative to

Fluctuations Relative to

WT

WT
M223A

G224D

80, 81, 82, 106-111, 113,

32-36, 39, 48, 49, 58-61, 64, 70, 100, 101, 102, 103,

114, 116, 211, 212, 221-

104, 120, 121-123, 125, 130, 131, 134, 135, 139, 158,

228, 253, 254, 274, 275

162-165, 168-171, 192, 239, 240, 256-259, 261

69-71, 81, 82, 107, 108,

32-38, 44-50, 58-60, 64, 74, 92, 93-104, 110-113, 115,

169, 222-227

117, 118, 120, 121-123, 125-131, 135, 136, 138-148,
150-152, 156, 161, 162, 184, 185, 187-190, 192-204,
206-210, 212-215, 236-244, 254-270, 272

P227S

60, 61, 67-72, 82, 211, 222-

32-37, 48, 49, 99, 100, 105-109, 111-114, 116, 122-

227, 253, 275

131, 164, 165, 168, 169, 204, 205, 238-242, 255-259

Table 4: Residues with Decreased/Increased Fluctuations Relative to WT. A
decrease means a ΔRMSF < -0.1Å, and an increase mean a ΔRMSF > 0.1Å. Residue
numbers are colored according to the structural motif on which they are located, blue is β5β6 loop, green is P loop, red is Ω loop, and orange is catalytic PASTFK motif.

As seen from the ΔRMSF calculations, all three β5-β6 loop mutations decrease
the overall fluctuations of the loop. At least some part of the catalytic PASTFK motif also
decreases in flexibility across the mutants – typically Thr82. Some residues in the Ω loop
see consistent increases in total fluctuations relative to the WT as well (generally the
residues around Gln162); particularly so in the M223A mutant. Curiously, all of the
mutants’ N-termini (residues 32-40, part of helix 1) fluctuate greatly over the WT
enzyme.
Differences between the enzymes are primarily in the P loop. The area of the P
loop around Thr111 fluctuates highly in the G224D trajectory. Of interest is the adjacent
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residue Tyr112, which forms a hydrophobic bridge with Met223. This bridge has been
implicated in ligand binding and selectivity (Schneider 2011). The RMSF for Tyr112’s
Cα in the WT and G224D trajectories are 1.44 Å, and 2.47 Å respectively. The P227S
mutant as well shows increases in P loop flexibility over the WT. RMSF of Tyr112 also
increases, but Asp106 in particular shows large a large increase in fluctuations. The
M223A mutant shows a different behavior with the first (N-terminal) portion of the loop
experiencing increased fluctuations, while the latter half shows decreased fluctuations.
Leu70 in M223A shows an extraordinary increase in RMSF over the WT. Leu70
is exposed to solvent, on the α2 helix, and is approximately 22 Å from the site of the
M223A mutation.
Another residue of interest is Val169 in the G224D mutant, which is the only Ω
loop residue to have decreased fluctuations relative to the WT; the other mutants have
some Ω loop residues with increased fluctuations, but none with decreases.
2C. Average Conformations
In order to evaluate how the above changes impact the structure of each enzyme,
we have calculated trajectory average structures. Average structures are limited in that
side chain atoms’ positions invariably become unphysical. However, they are appropriate
for comparing backbone conformational changes between mutants. Average structures
for each protein were determined using Script 5 (Appendix B). Average structures were
aligned by all Cα atoms to allow for comparison. The comparison between the WT and
mutant average structures is below (Fig. 14); the Cα RMSD between the mutant
structures and WT are given in Table 5.
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Fig. 14: Average Structures.
WT average structure colored
blue, M223A average structure
colored purple, G224D colored
green, and P227S colored red.
Proteins were aligned by all
Cαs.

P Loop

Ω Loop
β5-β6 Loop

RMSD (Å)

M223A

G224D

P227S

1.37

1.15

1.18

Table 5: Cα RMSD between WT & Mutant Average Structures.
Common amongst the mutants’ average structures is the shift of the P loop away
from the β5-β6 loop. The Ω loop for all mutants has also shifted “downward” and closer
to the β5-β6 loop; the M223A mutant has shifted the closest with G224D showing the
least change relative to the WT. Also across all the mutants, the β5-β6 loops have all
shifted towards the Ω loop, and the Ω loops have all shifted toward the β5-β6 loops as
well. These trends are also illustrated by average distances between atoms in both of the
loops (Table 6).
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WT Avg. (Å)

M223A Avg. (Å)

G224D Avg. (Å)

P227S Avg. (Å)

Leu168Cα - Gly222Cα

7.94 ±1.07

6.45 ±0.44

6.59 ±0.38

6.71 ±0.37

Leu168Cα - Gly/Asp224Cα

7.85 ±0.97

6.78 ±0.70

7.05 ±0.47

6.68 ±0.78

Leu168Cα - Met/Ala223Cα

9.36 ±1.09

8.18 ±0.52

8.25 ±0.36

8.13 ±0.47

Val163Cα - Gly/Asp224Cα

7.87 ±1.39

6.43 ±0.88

6.42 ±0.39

6.24 ±0.58

Val163Cα - Val225Cα

8.92 ±1.44

6.61 ±0.83

6.45 ±0.48

6.34 ±0.50

Table 6: Atomic Distances between Ω & β5-β6 Loop. Distances selected from Table
16, Appendix C.

There are few other differences between the mutants’ average structures when
being compared to the WT. One of the few is the shift of the α3 helix (containing the
catalytic PASTFK) towards the ligand-binding space in the M223A and P227S mutants,
but not G224D (Fig. 15, Table 7).

C-term

N-term

C-term

N-term

*

*

Fig. 15: Average Structures α3 Helix Shift. Left: WT colored blue, M223A colored
purple, P227S colored red. Right: WT colored blue, G224D colored green. *Ligand
binding space is located to the right of the helices in both images.
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WT Avg. (Å)

M223A Avg. (Å)

G224D Avg. (Å)

P227S Avg. (Å)

Ala80Cα - Gly222Cα

6.12 ±0.73

5.17 ±0.27

5.40 ±0.31

5.29 ±0.32

Ala80Cα - Trp221Cα

7.46 ±0.89

6.24 ±0.30

6.57 ±0.40

6.15 ±0.28

KCX84Cα – Ser219Cα

10.50 ±0.43

9.98 ±0.25

10.72 ±0.43

9.82 ±0.32

Ser81CA - Gly220Cα

4.87 ±0.25

4.70 ±0.24

4.83 ±0.20

4.61 ±0.25

Thr82Cα - Lys218Cα

6.65 ±0.44

6.02 ±0.20

6.66 ±0.35

5.89 ±0.24

Table 7: Atomic Distances between PASTFK & β5. Distances selected from Table 16,
Appendix C.

The other difference is found when examining the average structures of the WT
and M223A enzymes, Leu70’s Cα is shifted ~2 Å from the WT’s position. Leu70 saw a
large increase in fluctuations over the WT - as detailed in the previous section (Flexibility
of Mutants).
2D. Radius of Gyration
To determine the effect of the mutations on the compactness of the enzymes, we
calculated the Rgyr for all of the proteins’ heavy atoms (Fig. 16, Table 8).
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Fig. 16: Radius of Gyration. Rgyr values for all trajectories were determined using Script
4 (see Appendix B). Top: Rgyr comparing M223A and G224D to WT. Bottom: Rgyr
comparing P227S to WT.

Trajectory:
WT Avg.
M223A Avg.
G224D Avg.
P227S Avg.
18.0 ±0.1
18.5 ±0.1
18.3 ±0.1
18.2 ±0.1
Rgyr (Å):
Table 8: Average Rgyr Values. Average Rgyr values calculated using the last 22 nsec of
the trajectories.

All β5-β6 loop mutations appear to decrease the overall compactness of the
mutants, although the difference between the WT and P227S is not dramatic. Both
M223A and G224D are significantly less compact than WT throughout the majority of
their respective trajectories. M223A maintains higher Rgyr values from 5 nsec onward,
and G224D follows the same pattern until 30nsec when it begins to resemble the WT.
The P227S mutant is the most similar to the WT when examining the Rgyr. Only for
~18% of the trajectory – from 18 nsec to about 25 nsec – does the mutant consistently
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have greater Rgyr values than the WT. For the rest of the trajectory, they both share
relatively similar values, and thus a similar level of compactness. The G224D mutant
shows a similar trend, while also fluctuating to a less compact conformation from 5 to 12
nsec.
2E. Volume of Active Site
Because the size of the antibiotic and the corresponding size of the enzymatic
active site are essential in the substrate selectivity of class D enzymes, we sought to
determine how the volume of the active site was changing throughout the trajectories. A
volume-calculation script was written in Python by Brian Mullen (Mullen and Szarecka,
unpublished data). Each active site was defined using specific atoms selected from each
enzyme, as the M223A and G224D mutations introduce new atoms to the definition of
protein surface that is used to calculate volume. The binding pocket was divided into two
parts: upper and lower. The upper part of the pocket includes the P loop residues;
designed to reflect its contributions to active site volume (Fig. 17A-C). The lower part of
the pocket contains the other important elements (catalytic residues, Ω loop, β5-β6 loop),
and is designed to model their effects on the shape and size of the active site (Fig. 17D)
where the bulky functional groups of 3rd generation cephalosporins would have to fit
(refer to Fig. 5). The pocket was defined this way since an unpublished crystal structure
of OXA-24 in a complex with a 3rd generation cephalosporin showed that the antibiotic’s
occupancy of the active site was mostly limited by the space bordered by the β5 stand,
and the Ω loop (Mitchell 2015).
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*

*
B

A

*

*
D

C

Fig. 17: Atomic Selection of Active Site. A: Orientation 1 of the P loop-inclusive active
site selection. B: Orientation 2 of the P loop-inclusive active site selection. C: Orientation
of P loop-inclusive selection showing the Tyr112-Met223 bridge. D: Figure of the
“lower” active site, without P loop atoms. *P loop.

By creating two different selections for the active site, it is possible to see which
part of the active site is contributing most to volume changes. Fig. 18 depicts how the
“whole” (P loop-inclusive) active site volume changed over the trajectories for each
enzyme.
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Fig. 18: Whole Active Site Volume.

Fig. 19 shows the active site volume when P loop residues are removed from the
calculation. Table 9 shows the average volume and standard deviations of the two active
site selections.

Fig. 19: Lower Active Site Volume.

Whole Active Site Volume Lower Active Site Volume
Avg. (Å3)
Avg. (Å3)
236 ±34
135 ±19
WT
199 ±43
147 ±24
M223A
196 ±42
176 ±42
G224D
219
±51
173 ±37
P227S
Table 9: Average Active Site Volumes. Averages were calculated using the last 22 nsec
of the trajectory.
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The WT, which has the largest average whole active site volume, interestingly has
the smallest average lower active site volume. The mutants do fluctuate to higher
volumes, sometimes higher than the WT, but they all also fluctuate to lower volumes
(Fig. 18). The lower active site shows the tendency of the mutants to remain at a higher
volume, until the end of the trajectory where all of the enzymes to converge to similar
values (Fig. 19).
We have calculated the mean distances between each atom in the user-defined
active site, and the variances of those mean distances. Using these matrices it is possible
to determine which atoms are contributing to the fluctuations of the each active site’s
volume. Fig. 20 shows both the mean distances and distance variances of the whole
active site for the M223A mutant. Fig. 21 shows both the mean distances and distance
variances of the whole active site for the G224D mutant. Fig. 22 and 23 show the same
data for the P227S and WT enzymes respectively. Additionally, due to the fact that the
defined active sites between the P227S mutant and WT are identical in both total number
of atoms and atom numbering it was possible to create matrices representing the
differences between the two enzymes in terms of mean distances, and the variances. Fig.
24 shows both the differences between mean distances and distance variances of the
whole active site for the P227S and WT enzyme.
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Fig. 20: Mean Distance Matrix & Distance Variances for Entire M223A Active
Site. Right: Mean Distance Matrix. Left: Variance Matrix. Letters correspond to
groups of atoms found within a specific area of the protein. A: Residues 80-84; P: P
loop; L: Leu127 and Ser218; Ω: Ω loop; β5: β5 strand; β5-β6: β5-β6 loop; the last
small region corresponds to Arg261.
The heatmaps allow us to detail which residues contribute the most to the
fluctuation of the active site. Across all of the mutants, the distances between P loop
and the β5-β6 loop show most of the variance. The majority of the variance in the
fluctuations of the entire M223A active site stem from the distances between Tyr112
and the catalytic serine and general base, as well as all β5-β6 loop residues, Leu168,
and Arg261. The single largest point of variance within M223A is the distance
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Fig. 21: Mean Distance Matrix & Distance Variances for Entire G224D Active
Site. Right: Mean Distance Matrix. Left: Variance Matrix. Letters correspond to
groups of atoms found within a specific area of the protein. A: Residues 80-84; P: P
loop; L: Leu127 and Ser218; Ω: Ω loop;β5: β5 strand; β5-β6: β5-β6 loop; the last
small region corresponds to Arg261.
between KCX84’s OQ1 and Leu168’s CD2. This is likely caused by the tendency for
KCX84 to hydrogen bond with Ser81 and Lys218, instead of Ser81 and Trp167 – a ~6
Å shift. Variance in the G224D distances is a result of the fluctuations between
Tyr112, and all other atoms in the defined active site. The largest variances, across all
proteins, stem fromTyr112’s side chain oxygen atom in the G224D mutant. Met223’s
Cε also reveals an increased variance in its distance to active site residues (Ser81,
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Fig. 22: Mean Distance Matrix & Distance Variances for Entire P227S Active
Site. Right: Mean Distance Matrix. Left: Variance Matrix. Letters correspond to
groups of atoms found within a specific area of the protein. A: Residues 80-84; P: P
loop; L: Leu127 and Ser218; Ω: Ω loop;β5: β5 strand; β5-β6: β5-β6 loop; the last
small region corresponds to Arg261.
KCX84), Tyr112, and Leu127 and Ser128. The P227S mutant shows increases in
average distances over the WT between the P loop/Ser128 and the β5-β6 loop though generally these increases are not more than 1 Å – and the distances between
Val169 and the β5-β6 loop shows decreases. These results correspond well with the
previously determined average distances (Table 16, Appendix C). The largest increase
in variance – as with the M223A mutant– likely depicts the preference of the KCX
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Fig. 23: Mean Distance Matrix & Distance Variances for Entire WT Active Site.
Right: Mean Distance Matrix. Left: Variance Matrix. Letters correspond to groups of
atoms found within a specific area of the protein. A: Residues 80-84; P: P loop; L:
Leu127 and Ser218; Ω: Ω loop;β5: β5 strand; β5-β6: β5-β6 loop; the last small region
corresponds to Arg261.
residue to hydrogen bond with Lys218 over Trp167. The largest decrease in P227S
variance is between the side chain atoms of Tyr112 and Met223-Gly224; which may
suggest that the P loop is in a fixed conformation, despite being ~1Å further from the
β5-β6 loop. The WT shows the second greatest variance in P loop distances to the β5β6 loop, which may reflect the WT loop’s larger RMSF relative to the mutants.
Average distances also aid in describing which residues contribute to active site
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Fig. 24: Mean Distance &
Variance Difference
Matrices for P227S and
WT. Top: Difference
between mean distances.
Bottom: Difference between
variances of mean distances.
Differences were calculated
by subtracting WT values
from P227S values.
Therefore, red colors
indicate increases in average
distance and variance of
P227S over WT; blue colors
indicate the opposite.
Letters correspond to groups
of atoms found within a
specific area of the protein.
A: Residues 80-84; P: P
loop; L: Leu127 and
Ser218; Ω: Ω loop; β5: β5
strand; β5-β6: β5-β6 loop;
the last small region
corresponds to Arg261.
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β5-β6

WT Avg. (Å)

M223A Avg. (Å)

G224D Avg. (Å)

P227S Avg. (Å)

Leu168Cα - Glu251Cα

17.55 ±0.48

15.66 ±0.42

15.87 ±0.40

15.92 ±0.38

Leu168Cα - Arg261Cα

19.78 ±0.94

18.71 ±0.59

18.70 ±0.52

18.80 ±0.56

Leu168Cα - Met/Ala223Cα

9.36 ±1.09

8.18 ±0.52

8.25 ±0.36

8.13 ±0.47

Met/Ala223Cα - Arg261Cα

14.88 ±0.48

14.70 ±0.46

14.67 ±0.46

14.68 ±0.50

Met/Ala223Cα - Glu251Cα

10.71 ±0.37

10.31 ±0.33

10.67 ±0.37

10.55 ±0.37

Ser81Cα - Ser128Cα

7.90 ±0.52

8.77 ±0.48

8.09 ±0.43

7.51 ±0.82

Ser81Cα – Tyr112Cα

16.20 ±0.91

17.21 ±0.96

17.22 ±1.79

15.79 ±0.96

Ser128Cα - Ser219Cα

8.74 ±0.57

10.66 ±0.77

9.41 ±0.64

9.65 ±0.71

Ser128Oγ - Ser219Oγ

6.77 ±0.88

8.63 ±1.33

7.72 ±0.82

7.35 ±1.27

Tyr112Cα - Met/Ala223Cα

15.03 ±1.63

18.19 ±1.28

15.85 ±1.92

16.23 ±1.39

Table 10: Distances Across Active Site. Distances selected from Table 16, Appendix C.
volume differences (Table 10).
The average distances help show the P loop’s role in affecting the volume of all
mutants. There is a ~3 Å increase in the distance between the Cα atoms of Tyr112 and
Met/Ala223 in the M223A mutant, and ~1 Å increase the P227S mutant. Also observed is
an increase in the distance between the Cα atoms of Tyr112 and the catalytic Ser81 in the
M223A and G224D mutants. This is also seen when examining the heatmaps. The
distance between Ser128 and Ser219 increasing in all of the mutants also shows an
opening of the active site. Ser128 acts as part of the “roof” of the active site, while
Ser219 is located just prior to the β5-β6 loop. The distance between the Ω and β5-β6 loop
is shown to decrease based on the average distances (Leu168 to Met/Ala223), and the
mean distance heatmaps as well; this was observed in the previous section which
described the average structures of the mutants.
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3. Further Analysis of P227S Mutation
Because the P227S mutation results in a particularly striking change in substrate
selectivity, additional analyses were carried out for this mutant. We examined how this
mutation might affect the enzyme in two different ways: (i) as a potential hydrogen bond
center, and (ii), with regard to substrate selectivity/ligand binding by docking antibiotics
to unique conformations from the WT and P227S trajectories.
3A. Ser227-Glu251 Hydrogen Bond
Replacing the proline should result in an increased dihedral freedom for residue
227, which in turn would allow the β5-β6 loop to explore more conformations. We
initially hypothesized that the P227S mutation would increase fluctuations of the β5-β6
loop. Interestingly, the dynamics observed during simulations reflect the opposite. As
detailed in the previous section (Comparison of Mutant Dynamics), the P227S mutation
results in a less flexible β5-β6 loop. The reason for this decreased flexibility is likely due
to the formation of a hydrogen bond between Ser227 and Glu251 (Fig. 25).
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Fig. 25: Ser227-Glu251 Hydrogen Bond. Top: Image taken from 20.2 nsec point.
Distance between donor and acceptor is 2.65 Å. Distance between hydrogen and acceptor
is 1.69 Å; donor-hydrogen-acceptor angle is 176°. Bottom: Other hydrogen bond donors
in close proximity to Glu251. Figure adapted from Mitchell et al. (2015).
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Based on the hydrogen bonding criteria of a donor-acceptor distance of <3.2 Å
and a donor-hydrogen-acceptor angle of 120°-180°, Ser227’s Oγ hydrogen bonds to
Glu251’s Oε atoms during 76% of the trajectory (Fig. 26), with an average donoracceptor distance of 2.73 ±0.99 Å while the hydrogen bond is formed (average over
trajectory is 3.84 ±0.99 Å). In the WT trajectory, Pro227’s Cγ is within a similar distance
during 0.4% of the trajectory; Glu251 instead hydrogen bonds with Lys253, Arg72, and
Gln52 for 33%, 29%, and 14% of the trajectory respectively. None of these interactions
with Lys253, Arg72, and Gln52 are present in the P227S trajectory to the same extent;
Glu251 in the P227S mutant hydrogen bonds to Lys253, Arg72, and Gln52 for 6%, 3%,
and 7% of the trajectory respectively.

< 3.2Å from Glu251 Oε1

< 3.2Å from Glu251 Oε2

> 3.2Å from Glu251 Oε

Fig. 26: Hydrogen Bonding Distance. Bars represent the distribution of frames with
Ser227 (Oγ atom, red) or Pro227 (Cγ atom, black) residing within the hydrogen bonding
distance from Glu251 or outside of this range. Angle criteria is not presented in figure as
comparison with WT would not be possible. Figure adapted from Mitchell et al. (2015).
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3B. Exploration of β5-β6 Conformations using RMSD
As we have observed changes in the overall RMSD and RMSF profiles of β5-β6
loop in the two proteins, it was likely that the loop may have different conformational
ensembles. We used loop RMSD as the criterion to identify conformational clusters
within each trajectory. Trajectories were aligned by all Cα atoms, and the RMSD of the
β5-β6 loop was calculated. The RMSD values were sorted in the ascending order, and
every 0.5 Å increment was specified as a bin. RMSD values from 0-0.5 Å were
designated as Bin 1, 0.51-1.0 Å was Bin 2, etc. Two structures from each RMSD range
was saved for comparison – the very first and middle structure of each 0.5 Å range of
RMSD values. The structures acquired can be seen below in Fig. 27.

WT

P227S

β5-β6

β5-β6

loop

loop

Fig. 27: WT & P227S Binned Structures. Left: WT structures. WT reference frame
(frame 0) in dark blue. Right: P227S structures. P227S reference frame (frame 0) in red.

The WT trajectory contained 10 bins, P227S contained 7 bins, indicating that
there is greater conformation diversity in the WT enzyme. This finding is consistent with
our previous RMSD/RMSF data. The β5-β6 loop adopts two main conformation in the
P227S mutant (Fig. 28). β5-β6 loops from the lowest, middle, and highest RMSD values
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can be seen below in Fig. 28A-B. The new conformations show a widening of the space
between the β5-β6 loop and the P loop (Fig. 28C-D), a trend which is not seen in the WT.

B

A

*

*

C

Met223 D

Tyr112

Met223

Tyr112

Fig. 28: Selected β5-β6 Loop Conformations from Binned Structures. A: Loops from
WT trajectory. Reference frame is blue, 0.29 Å structure in cyan, 2.23 Å structure in
yellow, 4.57 Å structure in green. B: Loops from P227S trajectory. Reference frame is
red, 0.30 Å structure in cyan, 1.51 Å structure in yellow, 3.05 Å structure in green. C:
Side chain positions in WT binned structures. D: Side chain positions in P227S binned
structures. Trajectories aligned by all Cα atoms. *Ω loop located to left of β5-β6 loop in
figures. C-D adapted from Mitchell (2015); ceftazidime (magenta), aztreonam (blue).

3C. Docking of Doripenem to Selected Trajectory Frames
Identification of different, unique conformations present in the P227S and absent
in the WT trajectory would allow us an opportunity to explore different binding modes of
antibiotics. Docking simulation of diverse ligands to multiple protein target frames not
only has a potential to explain the ligand selectivity, but also allows us to incorporate
some protein flexibility aspects into the overall docking results. In this part of the project,
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we conducted a set of preliminary tests on a small number of selected frames for
doripenem binding. The following sections described the process, docking parameters,
and selected frames.
3C-1. Docking Protocol
The docking protocol would be considered accurate if crystallographic
conformations of the acylated antibiotic could be reproduced sufficiently, and if the
binding affinity (Km, calculated by AutoDock as Ki) were consistent with in vitro values.
The crystal structure used for the validation was OXA-24 complexed with doripenem
(contained KCX84D mutation to prevent deacylation, PDB 3PAE) (Schneider 2011). The
Hγ present on Ser81 was removed to best represent the physiologic state of the enzyme
when using the acylated form of the antibiotic for docking (in general, hydrogens were
added only to all polar atoms in the protein target).
Our first goal was to determine which Lamarckian GA settings will produce the
closest agreement between the experimentally determined ligand conformation and the
predicted one. As criteria we used distances between (i) Leu168 and doripenem’s 6’
carbon, (ii) Ser81 to the β-lactam rings’ carbonyl carbon, (iii) doripenem’s carboxylate
oxygens to Arg261, and (iv) Trp221’s backbone nitrogen to the β-lactam’s carbonyl
oxygen. We have tested both acylated doripenem (cleaved β-lactam ring), and intact
(Michaelis complex) doripenem. Optimized Lamarckian GA parameters were population
size, number of energy evaluations, number of GA runs, box size, and grid spacing. The
Lamarckian GA parameters were optimized when computational time was minimized
while still acquiring satisfactory docking results. A large population size (750
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individuals) produced results that best represented the crystal structure. Grid spacing was
reduced from 0.325 Å to 0.225 Å, and the size of the grid box was altered to include
residues which are important for receptor-ligand interactions. Final CPU time was ~20
minutes per GA run.
3C-2. Docking of Acylated Doripenem
Fig. 29 shows a comparison between the crystallographic acyl-doripenem, and the
docked conformation. Table 11 details important interactions between acyl-doripenem
and the OXA-24 active site.

B

A

Ser81
D

C

Leu168

Trp221

Arg261
Ser128
Fig. 29: Comparison of Acyl-Doripenem Structures. A: Structure drawn in Licorice
and colored purple is the acyl-doripenem from 3PAE. The RMSD between the docked
acyl-doripenem and the crystallographic acyl-doripenem is 1.4 Å. B-D: Structure drawn
as ball-and-sticks is the docked acyl-doripenem. Residue hydrogens not present in crystal
structure.
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The predicted (docked) orientation of the ligand is correct with respect to the
binding of the carboxylate to Arg261, and the 6’ carbon/Leu168 interaction. This is a
very positive outcome as the carboxylate group likely serves as the positioning anchor for
the antibiotic with respect to the catalytic residues.
Among the differences between the docked acyl-doripenem and the
crystallographic structure is that the 6’-oxygen atom has shifted to hydrogen bond with
Ser128’s backbone oxygen (Fig. 29D) instead of being oriented towards Tyr112. The 2 Å
difference in the distance from Ser81 to the cleaved β-lactam carbonyl carbon may be a
result of the lack of the enzyme-antibiotic covalent bond, as this could not be modeled
using AutoDock4.
3C-3. Docking of Doripenem Michaelis Complex
To be able to compare the calculated binding energy with the experimental Km for
doripenem, an un-acylated version was docked to WT OXA-24. Unfortunately, the
Michaelis-complex of doripenem and OXA-24 has never been determined using X-ray
crystallography, so a direct comparison of the docked results to a crystal structure is not
possible. Fig. 30 shows the docked doripenem structure in the OXA-24 active site.
Ser128

Leu168
Arg261
Trp221
Fig. 30: Docked Michaelis Complex of Doripenem.
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Ser81

Docked Acyl-

Ser81 Oγ to

Leu168

Trp221

Arg261 Side-chain

β-lactam

to 6-

Backbone

Nitrogens to

Carbonyl

carbon

Nitrogen to β-

Doripenem

Carbon (Å)

(Å)

lactam Carbonyl

Carboxylate

Oxygen (Å)

Oxygens (Å)

3.3

3.7

3.3

2.7, 2.7

2.7

3.5

2.6

2.7, 4.3

1.3

3.2

2.7

2.9, 2.8

Doripenem
Structure
Docked
Doripenem
Structure
PDB 3PAE

Table 11: Docked Doripenem Comparison in WT OXA-24. Values given are distances
between specified atoms.

A number of interactions present in the crystallographic acyl-doripenem structure
are also present in the docked Michaelis complex (Table 11). Namely the 6’ carbon and
Leu168, and the interaction between Trp221 and the carbonyl oxygen on the β-lactam
ring. The distance between the catalytic serine and the β-lactam carbonyl carbon has also
decreased. Interestingly, one of the carboxylate oxygen atoms of doripenem has hydrogen
bonded to Ser128’s side-chain oxygen (2.7 Å; Fig. 30, left) instead of Arg261 as seen in
the crystal structure. The calculated Km is 0.032μM; the experimental Km of OXA-24 for
doripenem is 0.024 ±0.003μM (Kaitany 2013).
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Since key interactions were observed in both the docking of the acyl-doripenem
and the Michaelis complex with good agreement, we proceeded to select unique
structures in both the WT and P227S trajectories for the docking of the doripenem
Michaelis complex. Although the previous RMSD-based analysis of conformational
clusters provided interesting insights into the dynamics of the β5-β6 loop, we decided to
pursue a different analysis (of distribution of Φ and Ψ values) that would allow us to
identify more precisely unique structures to serve as docking target frames.
3C-4. Selection of Structures using Φ/Ψ Analysis
The selection of the WT and P227S structures based on the β5-β6 loop Φ and Ψ
angles revealed which residues contributed the most to the structural differences of the
loop structure between the two enzymes. Gly222, Met223, Gly224, Val225, Thr226, and
Gln228 were found to occupy similar dihedral ranges in both enzymes (Fig. 31).
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Met223

Gly222

Gly224

Val225

Thr226

Gln228

Fig. 31: Φ vs. Ψ Angles of Non-Contributing β5-β6 Residues.
Because residues in Fig. 31 adopted the same ranges dihedral angles in WT and
P227S, conformational changes in the β5-β6 loop are unlikely to be caused by these
residues. Further analysis of these distributions would be carried out to confirm this.
However, Trp221, and Pro/Ser227 were found to adopt unique dihedral angles (Fig. 32).
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Trp221

Trp221

Pro/Ser227

Pro/Ser227

Fig. 32: Φ vs. Ψ Angles of Contributing β5-β6 Residues. Top graphs: Trp221 dihedral
ranges; Bottom graphs: Pro/Ser227 dihedral ranges. WT values colored blue, P227S
values colored red. Right graphs shows P227S data on top; left shows WT on top.

Thus, we were able to determine which residues in the loop adopt different
conformations in P227S versus WT. We also identified some unique frames in P227S
with Φ/Ψ values not observed in the WT, and vice versa that served as preliminary
targets for our comparative docking tests. Given the preliminary nature of this part of our
study the choice of unique frame was not rigorous. Further work including correlation
analysis will be required to fully determine a much larger number of docking frames.
For this project, two structures were selected from the trajectories corresponding
to unique Trp221 dihedral angles. A WT structure with Φ/Ψ values of -163.5°/85.1° was
chosen to represent the range of dihedral values that the WT enzyme primarily occupied
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(Fig. 32, upper right graph, Structure A). The corresponding P227S structure (Fig. 32,
upper left graph) chosen had Φ/Ψ values of -166.1°/128.0° (Structure B). A WT structure
with Φ/Ψ values of -24.9°/138.8° was chosen to represent the range of dihedral values in
which the WT enzyme occupies more highly than P227S (Fig. 32, lower right graph,
Structure C). The P227S structure chosen (Structure D) had Φ/Ψ values of -73.8°/126.0°.
A number of differences are present between the two structures chosen from the
Trp221 Φ/Ψ comparison (Fig. 33).

P Loop
Ω Loop
β5-β6 Loop
Fig. 33: Comparison of Structure A to Structure B. WT structure colored blue, P227S
colored red.
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The β5 strand does not end until Met223 in the P227S structure, and it ends 2
residues earlier in the WT at Trp221. The Ω loop in the WT structure acquires a partialhelix conformation from residues Phe166-Gly170.
Differences in the structures selected from the Pro/Ser227 Φ/Ψ analysis
(Structures C and D) are present as well (Fig. 34). Similar to the Trp221 structures, the P
loop of the P227S structure has moved away from the β5 strand, and the Ω and β5-β6
loops have shifted closer to each other. Unlike the Trp221 structures, both β5 strands end
at the same residue, and the Ω loop does not acquire a partial-helix conformation within
the WT structure.

Ω Loop

P Loop

β5-β6 Loop
Fig. 34: Comparison of Structure C to Structure D. WT structure colored blue, P227S
structure colored red.
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Table 12 reiterates the Φ/Ψ analysis, and the differences between the WT and
P227S structures selected for the docking of the doripenem Michaelis complex.
Structure

Φ (°)

Ψ (°)

Structure

Residue with

Acquired from

Unique Φ/Ψ

Trajectory

Value

A

-163.5

85.1

WT

Trp221

B

-166.1

128.0°

P227S

Trp221

C

-24.9°

138.8°

WT

Pro227

D

-73.8°

126.0°

P227S

Ser227

Table 12: Summary of Structures Acquired from Φ/Ψ Comparison.
These 4 structures were utilized with the previously described docking protocol
(section 3C-1) to determine if unique binding modes would be present between the WT
and P227S structures.
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3C-5. Docking of Doripenem to Selected Structures
The previously described 4 structures (A, B, C, and D) subsequently had
doripenem docked as the Michaelis complex. The docking of doripenem to these
structures (Fig. 35, Table 13) produced docked complexes which had few similarities to
the previously acquired Michaelis complex in Fig. 30. To try and acquire the two most
plausible docked conformations, one was visually selected on the basis of the receptorligand interactions previously seen in the acyl-complex and the Michaelis complex
(designated via “V.O.” in Fig. 35 and Table 13); another structure was selected which
had the most similar binding energy to that of the experimentally determined value
(designated via “B.E.” in Fig. 35 and Table 13).

Structure C B.E.
Leu168

Trp221

Ser81

Arg261
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Structure B V.O.

Leu168

Arg261

Ser81

Structure D V.O.
Leu168

Ser81

Arg261
Trp221

Fig. 35: Doripenem Docked to Selected Structures. Carboxylate circled in red, βlactam ring circled in yellow, 6’-hydroxyethyl circled in green. Not all docked ligand
complexes are depicted. Ligands shown above illustrate the best orientations acquired
from the docking. Top: Most similar binding energy to the experimental value. Middle:
Docked complex with most interactions present to some degree. Bottom: Nearly all
interactions present, with the best Ser81 Oγ to β-lactam interaction.
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Ki (μM)

Increase/Decr

Ser81 Oγ to β-

Leu168 to 6-

Trp221

Arg261 Side-

ease from

lactam

carbon (Å)

Backbone

chain

Experimental

Carbonyl

Nitrogen to β-

Nitrogens to

Binding

Carbon (Å)

lactam

Doripenem

Energy

Carbonyl

Carboxylate

(factor)

Oxygen (Å)

Oxygens (Å)

Ex. OXA-24

0.024 ±0.003

N/A

1.3

3.2

2.7

2.9, 2.8

OXA-24 M.C.

0.032

1.3x

2.7

3.5

2.6

2.7, 4.3

Ex. OXA-160

0.014 ±0.003

N/A

N/A

N/A

N/A

N/A

Structure A V.O.

13.62

567.5x

4.9

7.5

3.3

2.6, 3.1

Structure A B.E.

0.336

14x

8.9

15.8

8.3

2.7, 2.9

Structure B V.O.

194.76

8115x

3.7

7.8

2.9

2.8, 2.8

Structure B B.E.

0.209

8.7x

5.1

14.2

5.6

3.2, 4.2

Structure C V.O.

2.19

91.3x

4.4

6.3

2.9

2.9, 3.0

Structure C B.E.

0.115

4.8x

6.7

14.5

5.3

3.0, 4.3

Structure D V.O.

57.48

2395x

3.1

6.4

3.3

3.0, 3.3

Structure D B.E.

2.14

89.2x

7.4

14.8

6.6

6.5, 6.6

Table 13: Comparison of Docked Doripenem to WT/P227S Selected Structures. Ex.,
experimental; M.C., Michaelis Complex; V.O., Orientation selected visually; B.E.,
Orientation selected based on binding energy. Binding energies acquired from Mitchell et
al. (2015). Highlighted orientations are shown in Fig. 35.

Few of the docked structure resemble the Michaelis complex acquired during the
docking validation protocol. As we saw in the test runs, the majority of docked structures
contain the interaction between the doripenem carboxylate and Arg261, in fact the only
structure that lacks this interaction is the Structure D B.E. However, for this limited
number of target frames the remaining interactions between the antibiotic and the protein
binding pocket do not indicate productive binding. For example, the ligand orientation
with the most similar binding energy to the experimental values - the Structure C B.E. –
contains the antibiotic in a poor position for hydrolysis (Fig. 35, top). The 6’-
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hydroxyethyl is >14.7 Å from Leu168 and Ser81 is ~7 Å from its target atom on the βlactam ring. The sulfonamide tail of doripenem is also positioned on the opposite side of
the active site, near the Ω and β5-β6 loops.
The ligand orientation in the Structure D V.O. (Fig. 37, middle) is also incorrect.
Leu168 is 6.4 Å from the 6’-hydroxyethyl carbon, and the 6’-hydroxyethyl oxygen has
hydrogen bonded with the carboxylated lysine (donor-acceptor distance of 3.1 Å); an
interaction that is proposed to prevent the deacylation step of catalysis (Schneider 2011).
Only one ligand orientation has the Ser81 Oγ to β-lactam distance under 3.5 Å: the
Structure D V.O. None of the docked ligands have the Leu168 and 6’-hydroxyethyl
within sufficient distance for a hydrophobic interaction to occur.
In summary, much more work is needed in order to develop a rigorous method of
selected a large set of representative frames for docking, as well as to test more carefully
the potential energy function and distribution of atomic charges in our docking model.
The latter likely contributes to the problem with intact antibiotic binding.
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CHAPTER IV
DISCUSSION
1. RMSD
Based on the RMSD data presented, all three substitutions in the β5-β6 loop
affects the dynamics of OXA-24. The Ω and β5-β6 loops for the mutants all show less
structural drift from their initial conformation than the WT, while the P loops show
increased drift. The mutations also affect the active site of the enzyme. These effects are
discussed in detail in part 3 (Active Site Dynamics) of this discussion.
2. Compactness and Volume
Based on the Rgyr as a measure of protein compactness, all 3 mutants are less
compact than the WT. We hypothesized that the radius of gyration may be correlated
with the active site volume (widening of the cleft between the domains), but it turned out
not to be the case. Instead the volume calculations show the WT as having the greatest
average whole active site volume, despite the lower Rgyr. It must be noted, however, that
we traced the volume of the active site as a fraction of the entire cleft only. Interestingly,
the volume of the lower portion of the active site increases relative to the WT enzyme,
which supports the notion that a larger active site will allow the OXA enzymes to
potentially accommodate and hydrolyze larger antibiotic substrates. This is consistent
with X-ray data which shows that 3rd generation cephalosporins require additional space
between the Ω and β5-β6 loops to accommodate bulky substituents in the 6’ position.
However, a larger active site may not be the only factor necessary to hydrolyze larger
antibiotics. The G224D mutant also shows an increased lower active site volume relative
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to both the WT and P227S, yet the mutant has been reported to hydrolyze almost all
antibiotics less efficiently than WT OXA-24 (Leonard, unpublished data).
3. Active Site Dynamics
The active site is affected by mutations in the β5-β6 loop, despite having the
majority of the catalytic residues located ~10 Å from the mutations. The M223A
mutation appears to have the greatest impact on the dynamics of the active site. The
RMSD drift of the PASTFK, SxV, KSG motif, and Arg261in the M223A mutant show
the greatest increases over the WT. Conversely, the G224D mutation shows the least
effects on the dynamics of the PASTFK motif. The Cα drift of the motif in the G224D
mutant shows a decrease relative to the WT, while M223A and P227S are greater and
similar, respectively. The average position of the α3 helix bearing the PASTFK motif in
the G224D mutant is also the most similar to the WT.
All the available crystal structures show that the carboxylated lysine (KCX) has a
strong preference to interact with Trp167. In our trajectories, however, the network of
hydrogen bonds shifts and KCX bonds to Lys218- while maintaining the hydrogen bond
with Ser81. The WT enzyme shows the most frequent occurrence of this hydrogen bond,
with the G224D mutant being the 2nd most frequent, followed by the M223A mutant, and
the P227S mutant with the KCX-Lys bond forming less frequently. This rearrangement
of the hydrogen bond network within the active site has not been observed in crystal
structures. It is unknown whether this interaction is indeed formed in solution, but it
could potentially affect the carboxylation state of the general base. The environment
required to encourage carboxylation in OXA-10 is dependent on Trp154 (homologous to
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Trp167 in OXA-24) (Baurin 2009) and also on Val130 (Buchman 2012). The movement
of the KCX towards the lysine in the family K[TS]G motif may promote decarboxylation
if the distance is too great for the carboxyl group to interact with the hydrophobic
tryptophan. We cannot directly observe the decarboxylation process in the MD
simulations, so it is not clear what effect(s) the KCX84-Lys218 hydrogen bond would
have.
4. Loop Dynamics
All three mutations generally result in increased Ω loop flexibility (apart from
Val169 in the G224D mutant), and P loop flexibility. The M223A mutant is the only
enzyme in which some regions of the P loop have decreased flexibility. The P loop also
moves away from the β5-β6 loop consistently across all 3 mutants. The Tyr112CαMet223Cα distance in the WT, M223A, G224D and P227S enzymes are 15.0 ±1.6 Å,
18.2 ±1.3 Å, 15.9 ±1.9 Å, 16.2 ±1.4 Å respectively.
Surprisingly, all three 3 mutations in the β5-β6 loop mutations result in decreased
flexibility of the loop. All 3 loops with mutations show not only decreased RMSF values,
but the residue on the loop with the lowest flexibility remains relatively the same: both
Gly/Asp224 and Val225 have the lowest flexibility across all 3 mutants. This is
interesting when considering that mutations on either end of the β5-β6 loop affect the
fluctuations around the same region of the loop. β5-β6 loop flexibility and
conformational states have been studied in detail for the P227S mutant and the results are
described in subsection 5.
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Decreased β5-β6 fluctuations appear to correlate with increased P and Ω loop
fluctuations across the mutants in this study. This is an important observation but a more
extensive study would be necessary to show the motional correlation between the three
functional loops. The G224D mutation is common amongst the OXA-24 subgroup; it
appears in OXA-72, OXA-143 (Higgins 2009), OXA-182 (Kim 2010), OXA-253
(Girlich 2014), and OXA-255 (Zander 2014). It is possible that this mutation results in
the same dynamic changes in each enzyme, though it is unknown how other β5-β6
mutations (T226S in OXA-182, T226I in OXA-253) will affect the enzyme’s dynamics
in combination with the G224D mutation. In addition, longer simulation times are needed
to sample the proteins’ loop conformations sufficiently in general, and the lone P loop in
particular.
5. Thermostability of G224D Mutant
Based on our trajectories, we were not able to explain the reasons for the
increased thermostability of the G224D mutant. While the differences in Rgyr between
WT and G224D are statistically significant (p < 2.2x10-16), the increased Rgyr of G224D
does not indicate a more thermostable enzyme. It is likely that calculating solvent
accessible area (via Generalized Born/Surface Area model) would be a more appropriate
method. Another stability factor would be the introduction of hydrogen bonds, which has
caused increased thermostability in other enzymes (Zhang 2007). But Asp224 does not
form any hydrogen bonds with the protein throughout the entire trajectory. While the
backbone nitrogen atoms present on the Ω loop could be possible donors, the presence of
Leu168 and Val169 makes Asp224’s side chain rotation toward the Ω loop unfavorable.
We also considered decreased flexibility as a contributor to thermostability; many
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thermostable enzymes, or enzymes found in thermophilic organisms are less flexible than
enzymes found in non-thermophiles (Vihinen 1987). The G224D enzyme indeed shows
decreased flexibility relative to the WT in the β5-β6 loop, and, uniquely, Val169 on the Ω
loop. However, it also has the greatest number of residues with increased fluctuations
relative to the WT when compared to M223A and P227S. Therefore, based on our current
trajectory data we are unable to explain the phenomenon, and the increased
thermostability of the G224D mutant remains an open question.
6. Effects of Ser227-Glu251 Hydrogen Bond
The substitution of proline by serine introduces not only an increased
conformational freedrom for the C-terminus of the loop, but also a new hydrogen bond
center. The formation of the Ser227-Glu251 hydrogen bond rearranges the hydrogen
bond network around the site of the mutation, resulting in Lys253, Arg72, and Gln52
interacting less with Glu251. The hydrogen bond also affects the conformations of the
β5-β6 loop. The P227S mutant’s β5- β6 loop occupies two main conformational clusters.
These two distinct clusters show less variability than those of WT OXA-24. The RMSD
range of the conformations in the P227S mutant span about 0.3-3.1 Å, whereas the WT
spans 0.3-4.6 Å. The Tyr112-Met223 hydrophobic bridge is also wider in the majority of
these conformations, likely helping accommodate larger antibiotic substrates into the
active site. Thus, in the case of the P227S mutant, the decreased flexibility of the β5-β6
loop is likely caused by a new hydrogen bond, and a change in the conformational
ensemble.
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7. Concluding Remarks
The results in this work shed light on how the class D β-lactamases achieve
substrate profile changes with single amino acid mutations. Our trajectories showed the
conformational and dynamics changes caused by three specific mutations, each affecting
the substrate selectivity of the enzyme. In particular, we proposed a mechanism through
which the P227S mutant is able to expand its catalytic profile for 3rd generation
cephalosporins through active site volume changes, and a shift in the conformational
equilibrium of the β5-β6 loop.
The limitation of the work is the absence of the ligand. The binding of ligands can
drastically affect a protein’s conformation and function (Shaanan 1983; Fermi 1984), and
simulations of an acyl-enzyme complex will illustrate more accurately how class D
enzyme accommodate various antibiotics, and highlight associated changes in dynamics.
Particularly, the question of the carboxylated lysine’s variable hydrogen bond network
will likely be resolved through simulations of an enzyme-substrate complex.
These enzymes will continue to evolve and adapt to the pressures of new and old
drug therapies alike, But, understanding how mutations affect one subgroup can not only
help our understanding of all class D enzymes, but it can save lives as well as further
work will hopefully lead to the development of improved treatments for pathogens
producing these enzymes.
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APPENDIX A
KCX TOPOLOGY AND PARAMETERS
The topology and force-field entries for the carboxylated lysine (Simakov and
Wymore, unpublished data) are detailed as follows:
KCX CHARMM Topology
PRES KCX -1.00 ! Patch for carboxylated Lysine, ns
GROUP
ATOM CE CT2 0.060
ATOM HE1 HA 0.090
ATOM HE2 HA 0.090
ATOM NZ NECA -0.810
ATOM HZ1 H
0.300
ATOM CX CC 0.690
ATOM OQ1 OC -0.710
ATOM OQ2 OC -0.710
DELETE ATOM HZ2
DELETE ATOM HZ3
BOND NZ CX
BOND CX OQ1
BOND CX OQ2
IMPR CX NZ OQ1 OQ2

KCX CHARMM Force-field Parameters
Bond Parameters
CT2
H
CC

NECA

380.00 1.4300

NECA

440.00 1.0280

NECA

320.00 1.4617

Angle Parameters
CT3

CT2

NECA

67.70
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110.93

CT2

CT2

HA

CT2

CC

NECA

CT2
CC

NECA

67.70

110.93

NECA

51.50

107.50

CT2

50.00

115.00

H

60.00

110.00

H

60.00

110.00

OC

80.00

110.00

NECA
NECA

NECA

CC

Torsional Parameters
HA

CT2

CT3

HA

0.1600 3

0.00

HA

CT3

CT2

NECA

0.0400 3

0.00

HA

NECA

CT2

CT3

1.1000 1

180.00

CC

NECA

CT2

CT3

0.2000 3

0.00

CC

NECA

CT2

CT2

1.1000 1

180.00

CC

NECA

CT2

CT2

0.2000 3

0.00

0.0000 1

0.00

H
CC

NECA
NECA

CT2

HA

CT2

HA

0.0000 1

0.00

CC

OC

2.2000 2

180.00

CT2

NECA

CT3

CT2

NECA

H

0.2000 3

0.00

CT2

CT2

NECA

H

0.2000 3

0.00
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H

NECA

CC

OC

1.9250 2

180.00

Improper Parameters
CC

NECA

OC

OC

96.0000 0.0000

Non-bonded Parameters (L-J, ε, Rmin/2)
NECA

0.000000
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-0.200000

1.850000

APPENDIX B
TCL SCRIPTS
All syntax is presented in size 11 Courier New, single-spaced font. All scripts are
inputted as directed into the VMD Tk Console unless otherwise specified. Location
within the syntax where user-specified variables are defined are highlighted yellow.
Script 1: AnimateTRJs
proc animatetrjs {start end fileformat} {
set filename [format $fileformat [expr $start]]
incr start
puts "Reading initial frame in TRJ sequence $filename"
mol load dcd $filename
puts "Reading TRJ files as an animation..."
for {set i $start} {$i <= $end} {incr i 1} {
set filename [format $fileformat [expr $i]]
animate read dcd $filename
}
}

Use: To load .trj files consecutively into VMD. Copy and paste entire script into
VMD TK console. Trajectory files must be located within the current directory.
User-specified variables: N/A
Example Input: animatetrjs 5 50 “oxa24-wt-sys1-dyn%d.trj”
The above example loads all frames from oxa24-wt-sys1-dyn5.trj through, and including,
oxa24-wt-sys1-dyn50.trj.
Example Output: N/A
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Script 2: Load every other frame:
proc eo_frame {start end fileformat} {
set filename [format dcd [expr $start]]
for {set i $start} {$i <=$end} {incr i 1} {
set filename [format $fileformat [expr $i]]
mol addfile $filename type dcd step 2
}
}

Use: Similar to Script 1, except loads every other frame of the defined range of
trajectory files.
User-specified variables: N/A
Example Input: eo_frame 5 50 “oxa24-wt-sys1-dyn%d.trj”
Example Output: N/A
Script 3: Whole protein Cα RMSF
set outfile [open filename.dat w]
set sel [atomselect top "protein and name CA"]
set rmsf "[measure rmsf $sel]"
for {set i 0} {$i < [$sel num]} {incr i} {
puts $outfile "[expr {$i+1}] [lindex $rmsf $i]"
}
close $outfile

Use: Measures RMSF of all Cαs throughout the loaded frames, and prints the
residue-RMSF data into a .dat file within the current directory. Script must be pasted, in
its entirety, into the VMD Tk Console.
User-specified variables:
outfile  File to which all data will be outputted; named “filename.dat.”
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sel  Atomic selection for which RMSF will be calculated.

Example Input: N/A. Code runs automatically when copied and pasted into
VMD Tk Console.
Example Output: Script outputs two columns in the user-specified file. The first
column is the residue number, the second is the RMSF value in Å.
Example:
1
2
3
4
5

1.345243
1.190847
1.055538
0.868406
0.954798

Script 4: Radius of gyration
set mol [molinfo top]
set out [open filename.dat w]
set sel [atomselect top "protein and not hydrogen"]
for {set i 0} {$i <= 96000} {incr i} {
$sel frame $i
$sel update
puts $out "$i [measure rgyr $sel]"
}
close $out

Use: Measures the radius of gyration (not including hydrogens) throughout the
loaded frames, and prints the frame-Rgyr data into a .dat file. The user must specify the
filename to which the information is to be written [filename.dat]; and the number of
frames loaded
User-specified variables:
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out The file to which Rgyr data will be outputted; named “filename.dat.”
sel  Atomic selection for which Rgyr will be calculated.

Example Input: N/A. Code runs automatically when copied and pasted into
VMD Tk Console.
Example Output:
1
2
3
4
5

17.70242
17.75708
17.78677
17.82501
17.84038

Script 5: Average Structure
set var [atomselect top "protein"]
set averagestructure [measure avpos $var]
set newvar [atomselect top "protein"]
$newvar set {x y z} $averagestructure
$newvar writepdb filename.pdb

Use: Determines the average structure from the loaded frames, and outputs a PDB
file containing the corresponding coordinates. Script is run line by line in the VMD TK
Console.
User-specified variables:
var The selection to which average coordinates are to be determined.

Selections are defined using standard VMD syntax.
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filename.pdb  The filename to which the average coordinates will be

outputted in PDB format; named “filename.pdb.”
Example Input: N/A. Run code line by line in VMD TK Console.
Example Output: N/A. Output is a PDB file which can be opened normally in
VMD.
Script 6: Heatmap Generator
# Format the data into R matrices
row.names(matrix1) <- matrix1$Atom
row.names(matrix2) <- matrix2$Atom
matrix1_2 <- matrix1[,2:#1]
matrix2_2 <- matrix2[,2:#2]
m1dm <- data.matrix(matrix1_2)
m2dm <- data.matrix(matrix2_2)
# Create color palette
myPalette <- colorRampPalette(rev(brewer.pal(11, "Spectral")))
# Create Heatmaps
heatmap.2(MATRIX, Rowv=NA, Colv=NA, col=myPalette,
breaks=seq(0,20,by=0.1), symm=TRUE, trace="none",
dendrogram="none")
matrix1_heatmap <- levelplot(m1dm, col.regions=myPalette,
scales=list(x=list(rot=90)), ylab = "Y-Label", xlab="X-Label")
matrix2_heatmap <- levelplot(m2dm, col.regions=myPalette,
scales=list(x=list(rot=90)), ylab = "Y-Label", xlab="X-Label")
testmat <- m2dm – m1dm
diff_heatmap <- levelplot(testmat, col.regions=myPalette,
scales=list(x=list(rot=90)), ylab = "Y-Label", xlab="X-Label")

Use: Code produces heatmaps similar to Figs. 19-24. Requires the
following packages: gplots, Lattice, RColorBrewer. Script written by Brian
Mullen.
User-specified variables:
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#1  Input n-1 total matrix observations. In Example Input, wt2 had 76 total

observations, so 76-1=75.
#2  Input n-1 total matrix observations. In Example Input, p227s2 had 76 total

observations, so 76-1=75.
Example Input:
View(`p227s_full`)
`p227s` <- read.csv("~/Downloads/p227s_VarDistanceMatrix.csv")
View(`p227s`)
wt <- read.csv("~/Downloads/wt_VarDistanceMatrix.csv")
View(wt)
# Format the data into R matrices
row.names(wt) <- wt$Atom
row.names(p227s) <- p227s$Atom
wt2 <- wt[,2:75]
p227s2 <- p227s[,2:75]
wdm <- data.matrix(wt2)
pdm <- data.matrix(p227s2)
# Create color palette
myPalette <- colorRampPalette(rev(brewer.pal(11, "Spectral")))
# Create Heatmaps
wt_heatmap <- levelplot(wdm, col.regions=myPalette,
scales=list(x=list(rot=90)), ylab = "Y-Label", xlab="X-Label")
p227s_heatmap <- levelplot(pdm, col.regions=myPalette,
scales=list(x=list(rot=90)), ylab = "Y-Label", xlab="X-Label")
testmat <- pdm - wdm
diff_heatmap <- levelplot(testmat, col.regions=myPalette,
scales=list(x=list(rot=90)), ylab = "Y-Label", xlab="X-Label")

Example Output: See heatmaps in Figs. 19-24.

125

APPENDIX C
SUPPLEMENTARY DATA
α helix 1

α helix 2

β strand 1

β strand 2

α helix 3

α helix 4

α helix 5

α helix 6

α helix 7

β strand 5

β strand 3

β strand 4

β strand 6

Fig. 36: Secondary Structure Diagram of OXA-24. Secondary structure was assigned
by Schneider et al. (2011). WT OXA-24 contains a lysine in position 84, this structure
has an introduced aspartate mutation to prevent substrate deacylation. PDB 3PAE.
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Table 14: Percent Identity Matrix of OXA-24 Subgroup.
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WT
VAL78CG2
ALA80CA
ALA80CB
ALA80C
SER81N
SER81CA
SER81CB
SER81OG
LYS84CE
LYS84NZ
LYS84CX
LYS84OQ1
LYS84OQ2
TYR112CG
TYR112CD1
TYR112CE1
TYR112CZ
TYR112OH
TYR112CD2
TYR112CE2
TRP115NE1
TRP115CE2
TRP115CZ3
TRP115CZ2
TRP115CH2
LEU127O
SER128CB
SER128OG
SER128C
SER128O
TRP167CD1
TRP167NE1
LEU168CA
LEU168CB
LEU168CG
LEU168CD1
LEU168CD2
LEU168C
LEU168O
VAL169CG1
SER219CB
SER219OG
SER219O

M223A
VAL78CG2
ALA80CA
ALA80CB
ALA80C
SER81N
SER81CA
SER81CB
SER81OG
LYS84CE
LYS84NZ
LYS84CX
LYS84OQ1
LYS84OQ2
TYR112CG
TYR112CD1
TYR112CE1
TYR112CZ
TYR112OH
TYR112CD2
TYR112CE2
TRP115NE1
TRP115CE2
TRP115CZ3
TRP115CZ2
TRP115CH2
LEU127O
SER128CB
SER128OG
SER128C
SER128O
TRP167CD1
TRP167NE1
LEU168CA
LEU168CB
LEU168CG
LEU168CD1
LEU168CD2
LEU168C
LEU168O
VAL169CG1
SER219CB
SER219OG
SER219O

G224D
VAL78CG2
ALA80CA
ALA80CB
ALA80C
SER81N
SER81CA
SER81CB
SER81OG
LYS84CE
LYS84NZ
LYS84CX
LYS84OQ1
LYS84OQ2
TYR112CG
TYR112CD1
TYR112CE1
TYR112CZ
TYR112OH
TYR112CD2
TYR112CE2
TRP115NE1
TRP115CE2
TRP115CZ3
TRP115CZ2
TRP115CH2
LEU127O
SER128CB
SER128OG
SER128C
SER128O
TRP167CD1
TRP167NE1
LEU168CA
LEU168CB
LEU168CG
LEU168CD1
LEU168CD2
LEU168C
LEU168O
VAL169CG1
SER219CB
SER219OG
SER219O

P227S
VAL78CG2
ALA80CA
ALA80CB
ALA80C
SER81N
SER81CA
SER81CB
SER81OG
LYS84CE
LYS84NZ
LYS84CX
LYS84OQ1
LYS84OQ2
TYR112CG
TYR112CD1
TYR112CE1
TYR112CZ
TYR112OH
TYR112CD2
TYR112CE2
TRP115NE1
TRP115CE2
TRP115CZ3
TRP115CZ2
TRP115CH2
LEU127O
SER128CB
SER128OG
SER128C
SER128O
TRP167CD1
TRP167NE1
LEU168CA
LEU168CB
LEU168CG
LEU168CD1
LEU168CD2
LEU168C
LEU168O
VAL169CG1
SER219CB
SER219OG
SER219O

WT
GLY220N
GLY220CA
GLY220C
GLY220O
TRP221N
TRP221CA
TRP221CB
TRP221CG
TRP221CD1
TRP221CD2
TRP221CE3
TRP221C
TRP221O
GLY222CA
GLY222C
GLY222O
MET223N
MET223CA
MET223CB
MET223CG
MET223SD
MET223CE
MET223C

GLY224N
GLY224CA
GLY224C

VAL225N
VAL225CG2
ARG261CZ
ARG261NH1
ARG261NH2

M223A
GLY220N
GLY220CA
GLY220C
GLY220O
TRP221N
TRP221CA
TRP221CB
TRP221CG
TRP221CD1
TRP221CD2
TRP221CE3
TRP221C
TRP221O
GLY222CA
GLY222C
GLY222O

G224D
GLY220N
GLY220CA
GLY220C
GLY220O
TRP221N
TRP221CA
TRP221CB
TRP221CG
TRP221CD1
TRP221CD2
TRP221CE3
TRP221C
TRP221O
GLY222CA
GLY222C
GLY222O
MET223N
MET223CA
MET223CB
MET223CG
MET223SD
MET223CE
MET223C

ALA223N
ALA223CA
ALA223CB
ALA223C
GLY224N
GLY224CA
GLY224C

VAL225N
VAL225CG2
ARG261CZ
ARG261NH1
ARG261NH2

P227S
GLY220N
GLY220CA
GLY220C
GLY220O
TRP221N
TRP221CA
TRP221CB
TRP221CG
TRP221CD1
TRP221CD2
TRP221CE3
TRP221C
TRP221O
GLY222CA
GLY222C
GLY222O
MET223N
MET223CA
MET223CB
MET223CG
MET223SD
MET223CE
MET223C

GLY224N
GLY224CA
GLY224C
ASP224N
ASP224CA
ASP224CB
ASP224CG
ASP224OD1
ASP224OD2
ASP224C
VAL225N
VAL225CG2
ARG261CZ
ARG261NH1
ARG261NH2

VAL225N
VAL225CG2
ARG261CZ
ARG261NH1
ARG261NH2

Table 15: Atomic Selection of Active Site. Atoms highlighted in yellow represent the
additional atoms required to model the whole (“upper”) active site.
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Fig. 37: M-Coffee Multiple Sequence Alignment of Class D CPases. Values at top
represent percent of residues aligned identically between all multiple sequence alignment
methods. Individual residues are color-coded accordingly: red indicates perfect alignment
agreement between all methods, blue indicates the lowest agreement.

Fig. 38: G224D N-Terminal Outlier
Structures. Light blue: Reference frame. Dark
Blue: Peak present at ~5nsec in Figure 9. Red:
Peak present at ~17nsec in Figure 9. Cα atoms
of the N-terminal residue are colored yellow.
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Fig. 39: M223A Ser128, Val130 Outlier
Structures. Light blue: Reference frame. Dark
Blue: Peak present at ~7nsec in Figure 11 Other
Active Site Residues Cα Atoms. Ser128 Cα
atoms are colored yellow. Val130 Cα atoms are
colored red.

WT Avg. (Å)

M223A Avg. (Å)

G224D Avg. (Å)

P227S Avg. (Å)

Ala80Cα - Gly222Cα

6.12 ±0.73

5.17 ±0.27

5.40 ±0.31

5.29 ±0.32

Ala80Cα - Leu168Cα

4.65 ±0.33

4.50 ±0.34

4.61 ±0.29

4.81 ±0.52

Ala80Cα - Trp221Cα

7.46 ±0.89

6.24 ±0.30

6.57 ±0.40

6.15 ±0.28

Ala88Cα - Val201Cα

6.97 ±0.29

7.21 ±0.35

7.13 ±0.43

7.12 ±0.33

Arg138Cα - Asp164Cα

6.72 ±0.34

6.73 ±0.42

6.67 ±0.37

6.58 ±0.42

Arg138NH2 - Asp164OD1

3.57 ±0.93

3.64 ±1.00

3.65 ±0.95

3.58 ±0.96

Asn87Cα - Tyr133Cα

7.16 ±0.22

7.22 ±0.24

7.25 ±0.24

7.26 ±0.24

Asn87ND2 - Tyr133O

3.17 ±0.26

3.13 ±0.26

3.20 ±0.28

3.25 ±0.31

Gln134Cα - Asp164Cα

6.04 ±0.42

6.04 ±0.47

5.78 ±0.46

5.94 ±0.40

Gln134NE2 - Asp164O

3.36 ±0.76

3.48 ±0.88

3.35 ±0.81

3.71 ±1.12

Glu76Cα - Ile174Cα

5.61 ±0.33

5.12 ±0.27

5.06 ±0.27

5.28 ±0.26

Glu93Cα - Phe193Cα

6.70 ±0.31

6.56 ±0.27

6.61 ±0.29

6.53 ±0.27

Glu101Cα - Arg139Cα

14.04 ±0.34

15.48 ±1.14

14.33 ±0.81

13.95 ±0.36

Ile159Cα - Ile174Cα

12.08 ±0.31

11.90 ±0.31

11.96 ±0.30

12.01 ±0.32

Ile159Cα - Leu172Cα

5.45 ±0.28

5.39 ±0.29

5.46 ±0.28

5.45 ±0.30
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Ile159Cα - Phe166Cα

5.91 ±0.31

5.92 ±0.36

5.89 ±0.34

5.78 ±0.28

KCX84Cα - Val130Cα

8.65 ±0.34

8.68 ±0.53

8.98 ±0.50

8.83 ±0.40

KCX84HZ1 - Val130CG2

3.32 ±0.76

5.32 ±1.23

5.35 ±1.49

4.51 ±0.88

KCX84OQ1 - Lys218NZ

2.82 ±0.68

3.70 ±1.01

2.81 ±0.56

6.31 ±1.69

KCX84OQ1 - Trp167HE1

6.96 ±0.90

8.20 ±1.43

7.70 ±0.98

4.73 ±2.16

KCX84Cα – Ser219Cα

10.50 ±0.43

9.98 ±0.25

10.72 ±0.43

9.82 ±0.32

Leu92Cα - Thr197Cα

6.42 ±0.28

6.37 ±0.29

6.59 ±0.43

6.44 ±0.30

Leu142Cα - Val163Cα

5.41 ±0.29

5.54 ±0.42

5.57 ±0.41

5.33 ±0.26

Leu168Cα - Arg261Cα

19.78 ±0.94

18.71 ±0.59

18.70 ±0.52

18.80 ±0.56

Leu168Cα - Glu251Cα

17.55 ±0.48

15.66 ±0.42

15.87 ±0.40

15.92 ±0.38

Leu168Cα - Gly222Cα

7.94 ±1.07

6.45 ±0.44

6.59 ±0.38

6.71 ±0.37

Leu168Cα - Gly/Asp224Cα

7.85 ±0.97

6.78 ±0.70

7.05 ±0.47

6.68 ±0.78

Leu168Cα - Met/Ala223Cα

9.36 ±1.09

8.18 ±0.52

8.25 ±0.36

8.13 ±0.47

Leu168CD2 - Arg261NH2

12.87 ±1.31

12.42 ±1.39

11.74 ±0.86

13.75 ±1.36

Lys75Cα - Thr175Cα

5.65 ±0.21

5.56 ±0.21

5.58 ±0.23

5.59 ±0.21

Met/Ala223Cα - Arg261Cα

14.88 ±0.48

14.70 ±0.46

14.67 ±0.46

14.68 ±0.50

Met/Ala223Cα - Gln228Cα

5.38 ±0.35

5.08 ±0.32

5.34 ±0.32

5.35 ±0.34

Met/Ala223Cα - Glu251Cα

10.71 ±0.37

10.31 ±0.33

10.67 ±0.37

10.55 ±0.37

Phe83Cα - Trp167Cα

6.69 ±0.24

6.76 ±0.30

6.68 ±0.23

6.94 ±0.35

Phe154Cα - Ile159Cα

10.23 ±0.32

10.31 ±0.34

10.25 ±0.33

10.32 ±0.32

Phe154Cα - Leu168Cα

15.02 ±0.40

15.11 ±0.40

14.74 ±0.37

15.26 ±0.43

Phe154Cα - Phe166Cα

13.09 ±0.37

13.26 ±0.38

12.95 ±0.38

12.99 ±0.32

Phe154Cα - Trp167Cα

11.52 ±0.40

11.74 ±0.40

11.25 ±0.38

11.79 ±0.39

Phe154Cα - Val163Cα

15.56 ±0.38

15.79 ±0.48

15.50 ±0.44

15.60 ±0.37

Phe166Cα - Ile174Cα

12.24 ±0.27

12.52 ±0.29

12.26 ±0.27

12.43 ±0.26

Phe166Cα - Leu172Cα

6.36 ±0.34

6.34 ±0.36

6.20 ±0.35

6.22 ±0.26

Pro79Cα - Leu172Cα

7.45 ±0.25

7.52 ±0.25

7.53 ±0.24

7.44 ±0.27

Pro/Ser227Cα - Glu251Cα

6.99 ±0.35

7.01 ±0.28

7.20 ±0.34

7.06 ±0.27

Pro/Ser227CB - Glu251CD

4.29 ±0.56

4.27 ±0.47

4.56 ±0.63

4.15 ±0.45

Pro227CG - Glu251OE1

4.84 ±0.84

4.91 ±0.89

5.20 ±1.05

N/A
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Pro227CG - Glu251OE2

4.71 ±0.80

4.85 ±0.88

5.15 ±0.99

N/A

Ser81Cα - Gly220Cα

4.87 ±0.25

4.70 ±0.24

4.83 ±0.20

4.61 ±0.25

Ser81Cα - Ser128Cα

7.90 ±0.52

8.77 ±0.48

8.09 ±0.43

7.51 ±0.82

Ser81Cα – Tyr112Cα

16.20 ±0.91

17.21 ±0.96

17.22 ±1.79

15.79 ±0.96

Ser81CA - Val130Cα

8.60 ±0.54

8.72 ±0.52

8.74 ±0.57

8.55 ±0.46

Ser81Cα - Val130CB

8.21 ±0.59

8.23 ±0.70

8.50 ±0.74

8.32 ±0.62

Ser81HG1 - KCX84OQ2

2.91 ±1.42

4.64 ±1.06

1.89 ±0.38

3.69 ±1.12

Ser128Cα - Ser219Cα

8.74 ±0.57

10.66 ±0.77

9.41 ±0.64

9.65 ±0.71

Ser128OG - Ser219OG

6.77 ±0.88

8.63 ±1.33

7.72 ±0.82

7.35 ±1.27

Ser219Cα - Arg261Cα

7.68 ±0.38

7.88 ±0.42

7.40 ±0.38

7.82 ±0.41

Ser219CB - Trp221CB

7.49 ±0.29

7.34 ±0.28

7.60 ±0.27

7.28 ±0.28

Ser219OG - Arg261NH2

3.57 ±0.58

3.68 ±0.68

3.52 ±0.59

3.60 ±0.68

Ser227HG1 - Glu251OE1

N/A

N/A

N/A

3.04 ±1.13

Ser227HG1 - Glu251OE2

N/A

N/A

N/A

3.03 ±1.08

Ser227OG - Glu251OE1

N/A

N/A

N/A

3.85 ±1.01

Ser227OG - Glu251OE2

N/A

N/A

N/A

3.84 ±0.97

Thr51OG1 - Glu251O

2.77 ±0.15

2.76 ±0.15

2.80 ±0.19

2.79 ±0.16

Trp167Cα - Ile174Cα

9.66 ±0.27

10.07 ±0.30

9.74 ±0.25

10.08 ±0.25

Trp167Cα - Leu172Cα

5.96 ±0.39

5.86 ±0.39

5.74 ±0.38

5.88 ±0.35

Tyr77Cα - Ile174Cα

5.49 ±0.15

5.52 ±0.15

5.51 ±0.15

5.54 ±0.14

Tyr77Cα - Lys173Cα

5.52 ±0.24

5.25 ±0.22

5.17 ±0.21

5.33 ±0.23

Tyr77N - Ile174O

2.94 ±0.14

2.96 ±0.15

2.94 ±0.14

2.91 ±0.19

Tyr77O - Ile174N

2.83 ±0.12

2.89 ±0.13

2.86 ±0.12

2.91 ±0.14

Tyr112OH - Met114SD

7.87 ±1.20

8.17 ±0.63

8.87 ±2.68

8.33 ±0.90

Tyr112Cα - Met/Ala223Cα

15.03 ±1.63

18.19 ±1.28

15.85 ±1.92

16.23 ±1.39

Tyr112Cα - Ser128Cα

10.50 ±0.55

10.47 ±0.59

10.87 ±1.31

10.56 ±0.51

Tyr112CZ - Ser128CB

8.54 ±1.02

8.69 ±1.14

9.41 ±2.37

8.83 ±0.91

Tyr112OH - Met223CE

6.35 ±3.13

N/A

8.41 ±3.68

6.89 ±1.80

Val78Cα - Gly170Cα

6.09 ±0.33

6.12 ±0.39

6.08 ±0.27

5.97 ±0.29

Val78Cα - Val225Cα

9.11 ±0.89

8.24 ±0.40

8.09 ±0.27

8.17 ±0.34
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Val130Cα - Leu168Cα

10.00 ± 0.58

11.19 ±0.67

9.88 ±0.51

10.73 ±0.67

Val130CG2 - Leu168CD2

5.67 ±0.91

7.57 ±1.12

5.48 ±0.73

7.65 ±1.54

Val163Cα - Ile174Cα

17.34 ±0.27

17.61 ±0.37

17.39 ±0.28

17.66 ±0.36

Val163Cα - Leu172Cα

11.19 ±0.27

11.31 ±0.33

11.18 ±0.26

11.35 ±0.34

Val163Cα - Phe166Cα

6.22 ±0.23

6.37 ±0.30

6.36 ±0.22

6.50 ±0.29

Val163Cα - Gly/Asp224Cα

7.87 ±1.39

6.43 ±0.88

6.42 ±0.39

6.24 ±0.58

Val163Cα - Val225Cα

8.92 ±1.44

6.61 ±0.83

6.45 ±0.48

6.34 ±0.50

Val163CG1 - Gly/Asp224CA

7.80 ±2.00

6.43 ±0.88

5.28 ±0.48

4.73 ±0.73

Table 16: Average Distances of WT & Mutants. Measurements were calculated using a 1
nsec equilibration period.
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